Exhibitors #24, Biopartnering

Transcription

2KMM
Address
Al. Korfantego 79
40-161 Katowice
Poland
www
www.2kmm.eu
Organisation type
Company
Contact person
Name
Przemysław Mistur
Position
President
E-mail
[email protected]
Short description
2KMM is a trusted provider of comprehensive solutions and services supporting management and execution of research projects for pharmaceutical industry,
biotechnology, medicine and healthcare. As a contract research organization 2KMM CRO focuses on, and offers substantial expertise in eCRF design
and development, data management and statistical services.
Since 2005 2KMM has been conducting clinical/observational studies and running the registries of patients with the use of proprietary, cutting-edge electronic data capture
eCRF platform named GoResearch™.
The GoResearch™ is an innovative internet platform which offers a wide range of features such as:
- individually customized to the requirements of each study eCRF forms,
- real-time validation of registered data (Edit Checks),
- full tracking of data modifications (Audit Trail),
- configuration of information flow and adverse events management procedures (including automatic e-mail notifications for safety departments),
- query management with an option of automatic query generation,
- data entry verification module for Source Data Verification visits or manual entry Quality Assurance procedures,
- multilingual support,
- monitoring of study course and reporting,
- sites and users administration,
- all industry requirements and standards compliance (e.g. FDA CFR 21 Part 11).
Currently, during more than 30 international and local studies, observation data of more than 40.000 patients has been collected by almost 4.000 investigators from 1.800
sites on the GoResearch™.
2KMM holds certificates of implemented ISO 9001 Quality Management System and Information Security Management System, ISO 27001. The company has been also
awarded the statuses of preferred services provider for observational studies and data management as well as for custom IT solutions development.
2KMM IT services division also takes part in the provision of specialized systems and IT solutions. Our most important products have been successfully employed in clinical
research projects management, supporting the sales and numerous administrative activities.
For more information about 2KMM, please visit http://www.2kmm.pl/en/CRO-Services.aspx.
Partner profile:
Pharmaceutical/Biotech/CRO/Academic partner seeking professional and cost effective support in the area of electronic data capture, data management and statistics on either
international or local level.
ABA-Invest in Austria
BioPartnering
Address
Opernring 3
1010 Vienna
Austria
www
www.investinaustria.at
Organisation type
Other
Contact person
Name
Nataliya Kyrychenko
Position
Business Location Consultant Central and Eastern Europe
E-mail
[email protected]
Short description
ABA – Invest in Austria, the national investment promotion agency of the Republic of Austria, is the first point of contact for foreign investors.
Twenty-five qualified employees consult and support firms quickly, unbureaucratically and at no cost in establishing companies in Austria, and offer customized information to
international investors in the following areas:
•
Austria as business location – sectors, technologies and markets, political and economic conditions
•
Issues relating to site selection such as labor and tax regulations, incentives or real estate prices
•
Support in handling administrative procedures (operating licenses, funding applications, labor permits, visas, etc.)
•
Establishing national and regional contacts
•
Ongoing support for companies locating in Austria
•
Contact partner for expansion investments
In 2012 ABA – Invest in Austria provided professional consulting services to 201 international companies setting up business operations in Austria, accouting for a total
investment volume of EUR 282.37 millions. 2,385 new jobs were created as a result of these investments. On balance, ABA – Invest in Austria has concluded projects attracting
total investments of EUR 6.529 billion, creating 45,679 jobs, since its founding in the year 1982.
The Global Investment Promotion Benchmarking 2012 report of the World Bank Group ranked ABA - Invest in Austria as top glogal performer among 189 investment
promotion interdiaries (IPIs). Website (rank. 1)and inquiry handling (rank 7) were assassed.
Acadia Sp. z o.o. S.K.A.
BioPartnering
Address
Kazimierzowska 43/49
02-572 Warszawa
Poland
www
www.acadia.com
Organisation type
Company
Contact person
Name
Artur Chabowski
Position
President
E-mail
[email protected]
Short description
Artur Chabowski, President of Acadia, has been working in the corporate finance field since 1991. Through his 20+ years of experience he has developed a team of specialists
who are interested in new and unique companies. Acadia is fascinated with companies that are launching something innovative, providing a unique service or solution. In a
phrase: Acadia is out-of the box thinkers who are looking beyond the ordinary, looking for something extraordinary.
Acadia has been on the market since 2004 and has worked on numerous deals in Biotech, IT, food industry, medical, construction, Textile, and auto parts.
There are a number of business solutions, offered by Acadia, to choose from: Corporate Finance, NewConnect.
Whether buying a business, selling a business, advice on mergers, creating a joint ventures, management buy ins/outs, or raising financing for your business' plans, the Acadia
team will guide you through the process.
To learn more about Acadia, please visit:
www.acadia.pl
Since March 2014, Acadia is the exclusive representative for the American consulting firm - Regulatory Compliance Associates Inc.® in Central Eastern Europe.
______________________________________________________________
At Regulatory Compliance Associates® Inc. (RCA), we provide worldwide services to the pharmaceutical, biotechnology and medical device industries for the resolution of
complex compliance and regulatory challenges. We are an experienced and committed team of professionals having years of experience in FDA-regulated industries. RCA team
members are used to working alongside our clients to help them thrive in a highly regulated environment.
With personnel backgrounds that include every facet of R&D, operations, regulatory affairs, quality and manufacturing RCA brings experience, focus and scalability to its clients
and their regulatory matters. As partners, RCA can help negotiate the potential minefield of regulatory compliance with insight, hindsight, and the clear advantage of our
unique expertise and experience.
RCA remains highly active in the regulatory, compliance and quality community and are open to opportunities where we can share our thought leadership. To learn more about
our firm, please visit us at
www.rcainc.com
Adamed Sp. z o.o.
BioPartnering
Address
Pieńków 149
05-152 Czosnów
Poland
www
www.adamed.com.pl
Organisation Type
Company
Contact Person
Name
Marcin Szczeciński
Position
Government Incentives Manager
E-Mail
[email protected]
Short Description
Adamed Group, privately-held Polish pharmaceutical company established in 1986, in the past 28 years has become one of the leaders of the domestic pharmaceutical market.
Parallel to organic growth, in the beginning of a current decade, Adamed made two important acquisitions. Firstly, Agropharm, a Polish OTC product company was acquired,
which strengthened Adamed’s position in this market segment. Secondly, Polfa Pabianice, formerly state-owned enterprise with a broad portfolio of both ethical and OTC drugs
was bought. Consequently, Adamed Group was formed. In the meantime, internationalization efforts were pursued. Currently, Ada med Group has its daughter companies in
Spain, Ukraine, Russia and Kazakhstan. Today, our product portfolio consists of internationally marketed Rx & OTC drugs, dietary supplements and skincare products.
Historically, generic medical products have been a core business of Adamed. However, in 2001, we pioneered drug discovery in the Polish pharmaceutical industry. Through the
years we have built modern laboratory facilities and attracted leading scientists from Polish academia. Today, our research focuses on cancer and central nervous system
disorders, with its outcomes - biologic and small-molecule drug candidates intended for both, further own development and partnering. At present, Adamed Group has almost
1500 employees in Poland, 10% of whom is hired by the R&D Department.
Alabin sp z o. o.
Address
Sterlinga 27/29
Łódź 90-212
Poland
www
Alabin.pl
Organisation Type
Company
Contact Person
Name
Andrzej Woźniak
Position
Prezes Zarządu
E-Mail
[email protected]
Short Description
Alabin sp z o. o. is an internet B2B company, headquartered in Łódź, Poland. The company manages an e-commerce website, Alabin.pl gathering over 700 000 laboratory
products from 84 verified suppliers. This initiative is therefore, first and biggest B2B dedicated website, in the Polish life science sector. Making shopping easy. Company enables
fast contact between consumer and supplier, giving both sides variety of business tools. Alabin.pl gathers all reagents and laboratory equipment into one, scientific based,
technologically advanced catalogue. Thanks to detailed product descriptions and an advanced system of parameters, customer finds products tailored to fit his own needs. But
we decided to make a step further. A consumer can add products to his shopping list, and order them directly from many suppliers at once. Searching and acquiring medical
equipment has never been easier. Answering biobuissnes needs. All customers of Alabin.pl are verified. Majority of them are heads of laboratories and laboratory technicians,
who are interested in finding the best equipment. This high quality contact is appreciated by suppliers, and we strive to make it an indispensable part of Alabin.pl. Implemented
customer relationship management, live chat between contractors and capability to create customized offers, makes Alabin.pl an advanced internet marketplace dedicated to
laboratory products. Additionally Alabin employs a multi-level e-commerce strategy. As a B2B company, we have created a marketplace where every user can be a consumer
and a supplier simultaneously. By keeping track of all transactions and contacts in one place, we are redefining e-commerce in the Polish life science sector. Ever-growing
marketplace. Currently Alabin provides services for 84 Polish distributors form different areas of lifescience sector. Customers browse 700 thousand of products everyday,
compare prices and order supplies. New users join every day, as new technologies are implemented. Acquiring new customers motivates us to widen the offer. Currently, our
team is developing solutions, addressed directly to chemical industry, quality control facilities and calibration laboratories.
Altiora Ltd
BioPartnering
Address
20 Station Road
SL9 8EL Gerrards Cross
United Kingdom
www
Organisation Type
Company
Contact Person
Name
Josip Aralica
Position
Managing director & CEO
E-Mail
[email protected]
Short Description
Altiora is the Clinical Research Organization based in CEE region providing full service with regards to preclinical studies, studies phases I-IV including protocol writing, IB, IMPD
preparation, startup, submissions, study monitoring, project management, pharmacovigilance, final report preparation.
Analytical Services Dr. Ralph Nussbaum
BioPartnering
Address
Pauwelsstrasse 17
52074 Aachen
Germany
www
www.analytical-services.com
Contact Person
Name
Damian Leschik
Position
Head of Business Development
E-Mail
[email protected]
Short description
Analytical Services is the leading analytical contract research laboratory for special analytical questions. Pharmaceutical, biotechnology and medical device manu fac turer
worldwide rely on our high quality standard and fast analytical service. The laboratory of Analytical Services is GMP certified and offers pharmaceutical and bioanalytical
analyses exclusively for the pharma ceutical and biopharmaceutical industry, as well as for the medical device manufacturer. The full GMP compliance analytical service
include services as structure elucidation with state of the arte equipment and techniques (NMR/qNMR; LC-MS/MS; GC-MS, MALDI-TOF, semi and fully prepa rative HPLC,
dissolution etc.), isolation and synthesis of degradation products in Drug Substance and Drug Product. Method development, method validation (according to ICH
guidelines) and release analysis give the customers the full qualitycontrol package needed for clinical studies and filing. Furthermore, Analytical Services offers the
characterization and qualification of reference standards, planning and execution of Extractable & Leachable studies and toxicological assessments of impurities. Our
analytical experts guarantee a quick and target oriented solution beyond routine analytical requests and work.
Assign Clinical Research Poland Sp. z o.o.
Exhibitors #31, BioPartnering
Address
Zwycięstwa 10
44-100 Gliwice
Poland
www
http://www.assigngroup.com/
Organisation Type
Contact Person
Name
Mariusz Olejniczak
Position
GM Poland Chief Operating Officer Late Stage Projects
E-Mail
[email protected]
Short Description
Assign is a fully integrated biotech and pharmaceutical service provider. We pride ourselves on our flexible and experienced teams. Oncology, Cancer Immunotherapy, Vaccines
and personilzed medicine is our focus. We Understand Complex Clinical Development.
FACTS
Assign is a fully integrated, midsized pharmaceutical, medical device and biotechnology clinical services provider, headquartered in Germany and Austria.
We have the experience, expertise and global reach to support the clinical development of your products and technologies from Phase 0 through to IV. All of this within a
reasonable budget – we are right where you need us.
Known as the “right-size” CRO, Assign is large enough to conduct complex, global clinical trials, without compromising on the level of flexibility and responsiveness that ensures
your needs are placed first and foremost, always. This saves you valuable internal costs and project management resources, allowing you to focus on what you do best.
Assign has a broad range of therapeutic expertise and know-how, built up through years of successful delivery of complex clinical trials. In particular, Assign has accumulated
extensive skills in the therapeutic areas of oncology, cancer immunotherapy, vaccines, and personalized medicine. Our expertise in complex trials is based on the experience of
numerous studies.
MANAGMENT
Assign’s senior managers are clinical research professionals with extensive experience in the pharmaceutical, biotechnology and medical devices industries and clinical
development in all phases.
We understand the complexity of managing clinical development and the importance of therapeutic focus. Our clients benefit from this pool of expertise.
Internally, our project leaders administer, share and apply the knowledge that has been gathered through the management of international clinical studies. Assign offices have
native speakers for all involved countries.
There is no administrational overhead for organizations or countries that are not involved in your projects. This allows us to keep the overall study budget low, even for
international multicenter studies.
Until now, we have managed approximately 400 clinical studies, with more than 1500 study sites in 30 countries with 10.000+ subjects enrolled.
Assign is led by an executive committee that comprises a CEO, CFO, COO, CMO, QA and GMP experts, with a combined expertise in clinical development of approximately 100
years.
EXPERIENCE
You will benefit from Assign’s comprehensive experience in all stages of product development. Assign has a broad range of therapeutic expertise and know-how including
extensive skills in Oncology, Cancer Immunotherapy, Vaccines and Perosnalized Medicine.
However, Assign’s experience is by no means limited to these areas alone; with experience in more than 100 treatment indications, you can rest assured that Assign has the
knowledge
to
design
and
execute
your
clinical
development
program.
Assign has proudly been providing global clinical development support to Pharmaceutical, Biotechnology and Medical Device companies since 2002. During this time we have
conducted hundreds of trials covering more than various therapeutic areas through more than 1500 study centres in over 30 countries.
We are here for you every step of the way, offering the full suite of clinical development services. Our unique structure allows you to choose the combination of expertise and
services
you
need,
tailored
to
your
requirements.
Partner with us to gain access to our years of experience and global presence, reducing your product development time and giving your technology the best chance of success.
BBH Biotech
BioPartnering
Address
os. Raczyńskiego 1/3
www
www.bbhbiotech.com
Organisation Type
Company & Academia
Contact Person
Name
Mateusz Hoppe
Position
Board Member
E-Mail
[email protected]
Short description
BBH Biotech is a young company based in Poznań, whose main field of work is broadly defined industrial microbiology. Within the framework of t hese activities, BBH Biotech
has been developing ultrasound technology for microbiological purposes. Thanks to combining physics and biology, we obtain unique solutions that increase fermentation
efficiency on an industrial scale. We also offer a variety of alternative services for the industry that improve the production process, such as screening or strain modification.
Our well-equipped laboratory allows BBH Biotech to provide a range of microbiological services. Moreover, thanks to the infrastructure created in cooperation with Poznan
Science and Technology Park we are able to meet our customers' demands.
Bio-Tech Consulting Ltd.
BioPartnering
Address
27/29 Sterlinga
90-212, Łódź
Poland
www
http://www.biotechconsulting.eu/
Organisation Type
Company
Contact Person
Name
Tomasz Domagała
Position
Business Analyst
E-Mail
[email protected]
Short description
Bio-Tech Consulting Ltd. specializes in valuation and assessment of biotechnology R&D Projects. Our company cooperates with innovative companies that carry out research
and development, mainly by helping in the creation of startup companies. We organize trainings, conferences and biotech events (such as BioForum, Central European Forum
of Biotechnology and Innovative BioEconomy) for innovative biobusiness leaders.
Biofarm Sp. z o. o.
BioPartnering
Address
Wałbrzyska 13
60-198 Poznań
Poland
www
www.biofarm.pl
Contact Person
Name
Aleksander Galas
Position
Export Department Manager
E-Mail
[email protected]
Short description
Biofarm Sp. z o.. (Polish limited company) is one of Poland’s leading producers of pharmaceuticals founded in 1988. Armed with experience and modern technology, we have
long been helping to protect patients' health and improve the quality of their life. We are involved in research and development, manufacturing as well as retail sale and
marketing of pharmaceutical products both in Poland and abroad . With a global turnover of over 70 million EUR in 2011 Biofar m was ranked 19th among over 500
pharmaceutical companies from all over the world in the Polish market which makes us a serious player in the domestic field. Our company's competitive advantage is built
mainly on highly qualified staff and excellent product portfolio, which currently includes over 80 medicinal products and numerous dietary supplements. We are the proud
manufacturer of Polish leading OTC brands, such as Ginkofar, Bioprazol Bio, Magnefar B6, Soyfem or Halset, and a wide array of prescription drugs easily recognized by both the
practitioners and the patients. In 2001 Biofarm was one of the first polish companies granted with the GMP certificate confirming our compliance with the highest quality
standards for pharmaceutical production. This, together with constant development of our facility with state-of-the-art technology makes us a reliable partner. In our
laboratories equipped with modern devices we perform studies confirming the efficacy and safety of our drugs, in compliance with the EU regulations. Some of the recent
projects enjoyed EU funding, especially the Technological Initiative Programme which allowed us to gain even more competitive advantage. We are currently looking for a longterm collaboration with partners abroad, who would distribute and promote our products on local markets. However, we are also open for propositions of other forms of
cooperation.
BIOPHARM-LOGOS LLC
BioPartnering
Address
324,2-ya Zvenigorodskaya st. 13
b.43, Moscow, 123022
Russia
www
http://eng.bflogos.ru/
Organisation Type
Company
Contact Person
Name
Anna Shchitkovskaya
Position
Sales Menager
E-Mail
[email protected]
Short Description
The BIOPHARM-LOGOS company is the distributor of finished dosage forms, food supplements, medical devices, cosmetics on the Russian pharmaceutical market. The
BIOPHARM-LOGOS renders a full range of services concerning promotion of APIs, finished dosage forms, auxiliaries, food supplements and medical devices. It also renders
assistance in getting permission documentation for the realization of medicines and medical products in the territory of the Russian Federation.
biosaxony e.V.
Address
Tatzberg 47-51
D-01307 Dresden
Germany
www
www.biosaxony.com/en
Organisation Type
Other
Contact Person
Name
Urlike Novy
Position
Coordinator Marketing & Communications
E-Mail
[email protected]
Short Description
The biisaxony association represents the interests of more than eighty commercial companies, research centers and private player
in industry. Members strenghts, specializations and broad expertise are pooled and channeled into active projects. For example, working group develop strategic and scentific
targets which are then implemented within biosaxony. Since its foundation in December 2009 of biosaxony e.V. As association, biotechnology and related areas of engineering
ranging from the material sciences to medical equipment in Saxony have been represented by its members. By operating in the entire region of Saxony, biosaxony continuously
forgews new, effective network links and also acts as the spokesman and coordinator of the biotech industry vis-a-vis policymakers in Saxony. The sustained growth of the
biotech sectory is nurtured by the early involvement of stakeholders as well as coordinated strategy development and concerted action. As a result, biotechnology is now an
important pillar of Saxony's high-tech industry. In the ranking of Germany bioregions, Saxony is among the frontrunners – and in second place in eastern Germany (Source:
BIOCOM AG, 2012). Alongside our activities as Saxony;s biotech and life science association, collaboration with the sector elsewhere in Germany and abroad is vital for
successful cluster network. Among biosaxony's core tasks are appearing at key international trade shows and representing our network's interests as well as continuous project
– based collaboration with other bioregions.
BioTech a.s.
BioPartnering
Address
Tymiánová 619/14
Czech Republic
www
www.biotech-europe.eu
Organisation Type
Company
Contact Person
Name
Miloslav Korbel
Position
Product Manager
E-Mail
[email protected]
Short Description
Company BioTech is a becoming leader in distribution, technical and application support for hi-tech state of the art instrumentation in the field of life science, focusing in the
territory of Central and Easter Europe on technologies for Cellular Analysis and In vivo Preclinical Imaging.
Biotechpharma UAB
Address
Mokslininku str. 4
LT-08412 Vilnius
Lithuania
www
http://biotechpharma.lt/
Organisation Type
Company
Contact Person
Name
Edvinas Vosylius
Position
Business Development Manager
E-Mail
[email protected]
Short Description
Biotechpharma UAB is a biopharmaceutical contract development service provider. In state-of-the-art R&D and Manufacturing facilities we support different projects at any
stage of development. We have expertise in a biotechnological drug substance and drug product development as well as GMP compliant manufacturing. High quality and on
time performance is guaranteed by a team of highly qualified and experienced researchers, engineers, technologists and management professionals.
Biotechrabbit GmbH
BioPartnering
Address
Neuendorfstr. 24a
16761 Hennigsdorf
Germany
www
http://www.biotechrabbit.com/
Organisation Type
Company
Contact Person
Name
Wolfgang Jaeger
Position
Head of Sales
E-Mail
[email protected]
Biotehniskais Centrs, JSC
Address
Dzerbenes Str. 27
LV-1006 Riga
Latvia
www
http://www.bioreactors.net/
Organisation Type
Company
Contact Person
Name
Juris Vanags
Position
Managing director
E-Mail
[email protected]
Short Description
BIOTEHNISKAIS CENTRS (BTC), JSC main activities are connected with development and manufacturing of biotechnology equipment and customer specialized industrial process
automation. We offer standard and customized laboratory, pilot and industrial scale (till 3000 liters) bioreactors, which can be used for providing different processes of
microorganism cultivations. The main advantage of our bioreactors is the application of a novel magnetic drive and a user-friendly bioprocess control system. Additional
services are: The modernization of used bioreactors, the automation of different bioreactors and fermentations, installing of magnetic drives for mixing. We carry out ourselves
the test fermentations using our developed bioreactors.
BTC has the most comprehensive experience in Latvia executing process control projects in the water supply, waste water treatment equipment, pharmacy, chemical
technology, and energy industries, to name a few. These processes are carried out by using automation hardware and software products of different companies and
customizing them into best automation solution suitable for each particular process control application case. The quality system of Biotehniskais centrs, JSC is certified by
Bureau Veritas Certification according to ISO 9001:2008.
BioVirtus Research Sp. z o.o.
Exhibitors 30#, BioPartnering
Address
Mokra 7
05-830 Kajetany
Poland
www
http://biovirtus.eu
Organisation Type
Research organization
Contact Person
Name
Agnieszka Kulesza
Position
Clinical Operations & Marketing Manager
E-Mail
[email protected]
Short Description
BioVirtus Research Site is a privately held company specialized in early-phase clinical trials. We perform studies in a modern and fully equipped dedicated research facility
located in central Poland. BioVirtus offers comprehensive conduct of phase I, bioequivalence, and bioavailability clinical tr ials (including first-in-man) for international sponsors
and CROs.
BioVirtus provides a broad range of services performed within competitive timelines ranging from the pro-tocol design, through medical writing, IEC and regulatory
submissions, recruitment of subjects and patients, clinical conduct (including medical, laboratory and pharmaceutical procedures), project management, to the fi nal study
report preparation.
BioVirtus represents the unique combination of in depth expertise in early clinical research, an experienced research team, outstanding subject housing conditions and
expedited recruitment capabilities. The synergistic combination results in efficient performance of even the most complex studies and most demanding protocols.
We perform the following studies:
• First-in-Man.
• Phase I (healthy volunteers, renal and hepatic impaired patients).
• Phase I-IIa in patients with related disease.
• Proof-of-Concept.
• Bioequivalence.
• Bioavailability and drug metabolizm.
• Biosimilars.
• Therapeutic equivalence.
• PK/PD studies.
SUBJECTS’ SAFETY FIRST & QUALITY ASSURED
BIURO HANDLU ZAGRANICZNEGO 'AGEMA' EWA&MICHAŁ MATCZAK S.C.
4Address
Górnicza 18/36
91-765 Łódź
Poland
www
www.agema-lab.pl
Organisation Type
Company
Contact Person
Name
Michał Matczak
Position
Sales & Marketing Manager
E-Mail
[email protected]
Short description
Our company has been present on the Polish market since 1991.We offer the highest quality scientific and research and laboratory leading manufacturers. Based on many years
of experience we sell our equipment in scientific and industrial sectors. We have authorized and well-trained service. Our product catalog includes such devices as such :
bioreactors, microbioreactors, shakers, shakers with incubation, ice machines, incubators, freezers.
BLIRT S.A.
Address
Trzy Lipy 3/1.38
80-172 Gdańsk
Poland
www
www.blirt.eu
Organisation Type
Company
Contact Person
Name
Krzysztof Kur
Position
Head of DNA-Gdansk Department
E-Mail
[email protected]
Short Description
Established in December 2008, BLIRT is a leading Polish biotechnology company. BLIRT built its initial capabilities around discovery chemistry and has further enhanced the
integrated services with analytical services, bio-analytical services, process research, DMPK/ADME, toxicology, genomic services, biologics manufacturing services, antibody and
biological research reagent manufacturing. GLP Analytical services:
- Pharmacokinetics and Bioequivalence - ADME - Proteomic Analyses - Drugs and Cosmetics Analysis Protein services: - Protein Expression
- Antibodies - Cell Line Development - SPR DNA-Gdansk department develop and manufacture products for molecular biology: - EXTRACTME product series (DNA, RNA isolation
kits from wide range of materials) - PCR and Real-Time PCR reagents - Enzymes (Proteinase
K, Lysostaphin, SSB proteins, ligases, polymerases, reverse transcriptases etc.) - Educational Kits for laboratory classes in molecular biology
- RNA-related products etc.
BTM Mazowsze Sp. z o.o.
Address
Rydygiera 8 bld. 3A
01-793 Warsaw
Poland
www
www.btm-mazowsze.pl
Organisation Type
Institution
Contact Person
Name
Natalia Kleczyńska
Position
Office Manager
E-Mail
[email protected]
Short Description
BTM Mazowsze Sp. z o.o. is a non-profit company supporting commercialization of research results conducted in the scientific institutions in Warsaw, through professional
technology transfer management and rising private and public capital to finance innovative R & D. BTM also supports building relations and initiation of cooperation between
business and science in the emerging on the Ochota Research Campus BioTechMed Cluster.
Capsugel
BioPartnering
Address
Rijksweg 11
2880 Bornem
Belgium
www
http://capsugel.com
Organisation Type
Company
Contact Person
Name
Piotr Gruszczyński
Position
Territory Sales and Business Development Manager
E-Mail
[email protected]
Short Description
Capsugel is a global leader in providing innovative, high-quality dosage forms and solutions for the health care industry. With more than 100 years of experience, we provide a
comprehensive array of advanced solutions to pharmaceutical and nutritional customers from formulation through clinical and c ommercial supply. From hard gelatin, liquidfilled and vegetarian capsules, to product development and manufacturing services, we help our customers improve their product profiles and accelerate development and
commercialization timelines. Capsugel is headquartered in Morristown, NJ, employs 2,900 people, has 12 manufacturing and R&D facilities across three continents and serves
more than 4,000 customers in over a 100 countries. For additional information, please visit www.capsugel.com.
CARBOGEN AMCIS AG
BioPartnering
Address
Hauptstrasse 171
CH-4416 Bubendorf
Switzerland
www
www.carbogen-amcis.com
Organisation Type
Company
Contact Person
Name
Alexander Stratz
Position
Sales Manager
E-Mail
[email protected]
Short Description
CARBOGEN AMCIS offers a range of chemical development services to support all stages of drug development, including process R&D and cGMP material supply. We support a
variety of NCE projects such as late discovery, toxicology studies, clinical phases I through III, and in-market supply, including highly potent APIs. Our Centres of Excellence
enable clients to customise their projects. They include: Highly Potent API Supply with state-of-the-art containment Chromatography services for customised solutions
supporting the separation and purification of APIs and Intermediates Analytical Services for full analytical support, including characterisation, control of drug substance,
reference standards and stabillty studies Drug product supply of aseptically filled parenterals
CEE Equity Partners
BioPartnering
Address
Grzybowska 5a
Poland
www
Organisation Type
Company
Contact Person
Name
Jacek Slotala
Position
Partner
E-Mail
[email protected]
Short Description
Private Equity fund targeting investment opportunities across Central and Eastern Europe. The Fund has $500 million under management.
Celon Pharma Ltd.
Address
Ogrodowa 2a
05-092 Kielpin
Poland
www
www.celonpharma.com
Organisation Type
Company
Contact Person
Name
Monika Lamparska-Przybysz
Position
Head of R&D Department
E-Mail
[email protected]
Short Description
CELON PHARMA is a dynamically developing Polish biopharmaceutical company with the strong research and marketing orientation, which leads advanced scientific research
and
produces
modern
drugs.
We
have
a
challenging
and
inspiring
mission:
to
improve
the
quality
of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of
people around the world. Products for development are always chosen among those offering competitive advantage or unique features differentiating them from others. Celon
Pharma is a leader in research and development that enable the creation of a broad new class of human therapeutics. Celon has built a platform to develop a deep pipeline of
drug products to treat a wide array of important diseases. We invest in research that is set to find effective and innovative original drugs, which can be used for i.e.: cancer,
neurological disorders, diabetes and other metabolic disorders. Celon Pharma is located in Lomianki near Warsaw and emplys ap proximately 230 People. The most of Celon
researchers have PhD degree or are PhD students. R&D projects are developed by research team consisting of Innovative Drugs Research & Development Department.
Currently we carry on 10 projects.
Celther Polska Sp. z o.o.
Address
Ostrzykowizna 14A
05-170 Zakroczym
Poland
www
www.celther.com
Organisation Type
Biopharmaceutical
Contact Person
Name
Edyta Wodzińska
Position
Sales Specialist
E-Mail
[email protected]
Short Description
Celther Polska conducts internal R&D programs targeted to design own innovative drugs and diagnostic solutions mostly in the area of oncology, cell therapy and wound
healing.
R&D projects
Development of a new platform for anticancer drug screening (UDA – POIG.01.04.00-10-012/11-00)
Tumor cells spontaneously showing alteration growth factor receptor in vivo have failed to be culture under in vivo conditions. A new platform for anticancer drug screening is
developed to test chemical compounds designed against mutated form of the receptor.
Induced multipotent and pluripotent stem cells (UDA – POIG.01.04.00-10-011/11-00)
iPSC have propensity to form tumours. In contrary, multipotent stem cells appear to be less dangerous for prospective treatments, since they are not the source of teratomas.
We have developed new method of converting somatic cells, where de-differentiation is performed without reversing to pluripotency state.
New small molecule drugs for targeted cancer therapy (UDA – POIG.01.04.00-10-037/11-00)
Targeted cancer therapies are intended to interfere with cancer cells growth and progression by blocking specific molecular targets involved in functions related to their
division, cell movement and response to external signaling. The targeting approach developed by Celther Polska utilizes chemical compounds interacting with molecular
pathways triggered by mutated oncogenes. This mutated growth factor receptor is frequently amplified and overexpressed in prostate cancers and brain tumors.
Innovative cellular biodegradable dressing material applicable in chronic wounds and ulcers treatment (UDA – POIG.01.04.00-10-020/11-00)
A good dressing material should not only absorb the secreted substance, but also provide beneficial conditions for wound healing
Products on the market
Primary human cancer cell cultures from a variety of tissue sources, including breast, colon and prostate.
Induced pluripotent stem cells (iPS cells)
Celther iPS cells can be easily differentiated to iNS cells, induced cardiomyocytes or hepatocytes as well as other specialised cell lines.
Induced neural stem cells (iNS cells)
iNS cells are self-renewing, multipotent stem cells of nervous system, which in appropriate conditions can be differentiated into neurons, astrocytes, oligodendrocytes.
Induced Cardiomyocytes
Induced human Cardiomyocytes are derived from iPS cells and consist of beating areas containing contracting cardiomyocytes.
Product under development
Innovative cellular biodegradable dressing material applicable in chronic wounds and ulcers treatment (stage of development: clinical studies).
Services
1.
In vitro Toxicology testing
Celther Polska offers in vitro cardiotoxicity, hepatotoxicity and neurotoxicity testing based on neural stem cells, induced human cardiomyocytes and hepatocytes, derived from
iPS cells.
2. Cell biology:
Cell biology tests: Cytotoxicity, Growth and proliferation, Viability, Adhesion, migration and invasiveness, Apoptosis and necrosis.
Techniques: MTT, Cell observation in real-time microscopy and real-time fluorescent microscopy, Immunocytochemistry, Real-time measurement of cell adhesion and
proliferation using membrane conductance, Flow cytometry, Fluorescent microscopy
3. Genetic engineering:
Custom Gene Cloning services, Custom vector construction services
4. Cell cultures and iPS cell cultures
iPS cell line generation, stable cell line development service
5. Molecular biology
Next generation sequencing, RT-PCR, FISH, Sanger sequencing service, PCR-RFLP, Western blotting, Fluorescent microscopy services
Centrum Innowacji i Transferu Technologii; Akademia Medyczna we Wrocławiu
Address
T. Chałubińskiego 6
50-368 Wrocław
Poland
www
http://www.citt.am.wroc.pl/
Organisation Type
institution
Contact Person
Name
Justyna Seliga
Position
Consultant
E-Mail
[email protected]
Short Description
The Centre for Innovation and Technology Transfer
The Centre for Innovation and Technology Transfer (CITT) was established in 2006; currently, it operates within the Science and International Cooperation Division. The Centre is
a worthy successor to the Team for Inventions and Patent Protection created in the early sixties of the last century. In cooperation with researchers, the CITT drafts application
documentation regarding inventions, utility models and other protected items to be submitted to the Polish Patent Office; it also manages the affairs to be considered by the
Patent Office. The main tasks of the team working in the Centre include: (1) supporting research and implementation projects; (2) providing comprehensive assistance at the
planning stage of research in order to increase chances to obtain legal protection for research findings along with their effective implementation and commercialize them; (3)
helping to analyse inventive designs; (4) identifying and supervising the course commercialization processes (licensing, sales, establishing a company or consortium). In
addition, the Centre for Innovation and Technology Transfer provides support when it comes to establishing contacts with investors, entrepreneurs and research teams, and
helps to obtain funds for the development of innovative projects and their protection. For entrepreneurs the Centre is a source of information about R&D projects executed at
the University, apparatus base and possibilities of cooperation. It is a meeting place for researchers and entrepreneurs. The CITT undertaking have been many times praised by
the National Centre for Research and Development (NCRD), which resulted in awarding the Centre additional financing to intensify the process of technology transfer (within
such programmes as, for instance, Kreator Innowacyjności [Innovation Wizard], Patent Plus, Spin-Tech).
ChinaBio News
BioPartnering
Address
Room 406, No. 3 Building, No. 2568 Gudai Road
Shanghai
China
www
http://www.chinabionews.com/
Organisation Type
Company
Contact Person
Name
ZuHui Tang
Position
Journalist
E-Mail
[email protected]
Short Description
ChinaBionews is the marketing solutions provider for the Chinese healthcare industry, supporting our clients for their business expanding in the Chinese market. With two web
portals, www.chinabionews.com in English and www.bionews.com.cn in Chinese, we present the most updated industry dynamics, regulations, product info, and company
profiles for your understanding better of the Chinese market. We provide many kinds of solutions for your market entry and development in China, including product
registration, distribution channels, partnerships, media & public relations, digital marketing, and more customized consulting services. ChinaBionews is also the platform that is
supporting local companies for their global marketing. Please contact us for more information and further discussions. Email: [email protected] Phone: +8621-6155 7866 Website: www.chinabionews.com Website: www.bionews.com.cn (in Chinese) Address: Room 406, Building 3, No. 2568 Gudai Road, Shanghai 201108
CLINMARK
Address
Pelplińska 19
83-200 Starogard Gdański
Poland
www
www.clinmark.pl
Organisation Type
Company
Contact Person
Name
Iwona Marchut
Position
Manager
E-Mail
[email protected]
Short Description
CLINMARK is a leading Polish Contract Research Organization (CRO). Since 2001, we have been organizing, conducting and supervising the management of clinical
interventional trials phase I to IV as well as non-interventional studies. So far we have conducted more than 110 different research projects. The projects have been both: 1center as well as large multicenter, late phase studies in almost all therapeutic areas, as well as medical device studies. So far we have conducted more than 130 audits and
inspections in more than 30 countries all over the world. Clinmark’s effective management and conduct of clinical trials have geographically covered the areas of CE, EE, Africa
and Asia through our partners. Our service is centred around four main areas of expertise: Comprehensive conduct of interventional and non-interventional studies (from study
planning to preparation of the final report) Medical advisory service regarding program planning, possibilities and solving medical difficulties as they occur Independent quality
control Training – for business professionals as well as for doctors. Medical device: experience: In terms of medical device studies our experience puts us currently on the
leading edge of expertise in Poland. We have conducted majority of studies in the cardiovascular therapeutic area as part of international projects. So far we have conducted
more than 130 audits worldwide making us unquestionable experts in the area. We offer: Possibility of conducting virtually all possible audits – site audits, TMF, clinical labs
audits, database and system audits Preparation of research centres and departments to FDA, EMA inspections and to implementing corrective and preventive actions
Consulting and help in creation or reorganization of clinical departments, writing and optimizing internal procedures (SOP), creation of compliance departments, and last but
not least selection of subcontractors. Many years of experience in clinical research have enabled us to create optimally operating organization, a transparent and wellfunctioning structure as well as clear internal procedures. We have introduced a demanding training program that requires from our employees to upgrade their knowledge
and from us to assess their competences on a regular basis. We have a system of supervision of ongoing projects ensuring early identification of any potential problems. Our
staff comprise well educated medical doctors, pharmacists, masters of science (life sciences), who are deeply trained in clinical research (including ICH GCP, EU Directives, CFR,
local regulations, SOPs and therapeutic areas) and ISO 90001. Our management team are doctors and have more than 12 years of experience in clinical trials.
Druggability Technologies Holdings Limited
Address
Arthur Cox Building Earlsfor Terrace
Dublin
Ireland
www
www.drgtco.com
Organisation Type
Company
Contact Person
Name
Katalina Ferenczi
Position
Managing Director of Hungarian Subsidiary
E-Mail
[email protected]
Short Description
Druggability Technologies (DRGT) is a proprietary pharmaceutical product business dedicated to the development and commercialization of high-value pharmaceutical products
that deliver measurable and meaningful improvement in clinical efficacy. This mission is enabled through the deployment of the Company's Super-API Technology that delivers
substantial improvement in pharmacokinetics/pharmacodynamics/bioavailability resulting in high-value, proprietary products.
The proprietary high throughput (HT) Super-API technology delivers highly significant improvement in solubility, permeability and kinetics with unique properties unattainable
by traditional approaches and provides a basis for creating novel Super-API constructs with the opportunity to file new intellectual property.
DRGT not only applies its technology to compounds in development by BioPharma partners, but also to in-marketed drugs near or at the end of their proprietary life cycle
creating an internal pipeline of Super-APIs with improved clinical performance.
DRGT has successfully developed more than 30 Super-API versions of Bio-Pharmaceutical developmental or marketed drugs. These development efforts have created a skilled
and experienced scientific and management resource that is able to move compounds rapidly and securely from the active ingredient stage all the way through the creation of
novel and highly differentiated new Super-APIs and their pre-clinical evaluation. Proven benefits of the Super-APIs:
Enhanced solubility, dissolution rate and permeability characteristics that result in improved druggability profiles;
Solubility and pH independent absorption;
Faster onset of action;
Reduced or eliminated food effect;
Clinically relevant improvement in efficacy;
Solutions to eliminate harmful and toxic excipients;
More convenient administration route for improved patient compliance (e.g. IV to oral);
New composition of matter IP.
Dycem Limited
Address
Dycem Ltd Europe Ashley Trading Estate Bristol,
BS29BB
UNITED KINGDOM
www
http://www.dycem-cc.com/
Organisation Type
Company
Contact Person
Name
Marcin Gutu
Position
Contamination Control Specialist - Eastern Europe
E-Mail
[email protected]
Short Description
About Dycem Today, thousands of critical areas are protected by Dycem contamination control flooring solutions, which have been scientifically proven to be the most
effective, long lasting and high performance method of minimising foot, wheel and airborne contamination. Striving for innovation By striving for continuous improvement,
Dycem has developed the design and ability of its materials to trap and retain particles down to a nanoscale, reducing particle counts by up to 99.9%. Recognised as a worldleading manufacturer and supplier, Dycem has been producing polymeric contamination control zones since 1966, with headquarters in the UK, USA and the Philippines.
Dycem’s products are solely manufactured in the UK at its Bristol site and are sold globally in more than fifty countries to many of the world’s leading corporations. Dycem’s
reputation is reinforced by a host of testimonials from the company’s vast user-base, including world-leading organisations, such as Abbot, BMW, Bombardier, GlaxoSmithKline,
Heinz, Honda, IBM, Intel, Johnson and Johnson, Lilly, Motorola, Nestle, Nokia, Pfizer, Roche, Rolls Royce, Seagate, Sony, Takeda and Texas Instruments. Committed to
sustainability Dycem is committed to sustainability in its business, considering the environment at each stage of its operations, including the design of new products, sourcing
materials and suppliers, manufacture and delivery. Dycem’s environmental management system is recognised by its ISO 14001 certification, adhering to all relevant
international standards and demonstrating a commitment to quality, total customer satisfaction, product innovation and total compliance in the global market. This has earned
the company international recognition, establishing relationships and operating in a wide range of industries, including biotechnology, pharmaceutical, aerospace,
semiconductor, healthcare, medical device, fibre-optic, data centres, optical, automotive, packaging and food. With its flexibility and versatility, Dycem flooring can be bespoke
installed into almost any environment, with a range of options to suit a variety of contamination control needs.
EGC Seed Capital sp. z o.o.
Address
Żeligowskiego 3/5
90-752 Łódź
Poland
www
www.egcseedcapital.pl
Organisation Type
Company
Contact Person
Name
Tomasz Chmielecki
Position
Member of The Board
E-Mail
[email protected]
Short description
EGC Seed Capital was created with support of EU-backed Innovative Economy Operational Programme - "Initiating innovative activities." We support the development of
innovative projects especially in areas of life sciences, environmental protection and new technologies. Our offer is addressed to entrepreneurs and originators seeking the capital
and advisory support in the early stages of their ventures. Our team of experts has successfully managed venture capital funds since 2006. We have analysed thousands of
business plans and turned dozens of ideas into functioning companies. We strongly believe that a good idea of a product or a service, combined with our experience, knowledge
and financial support maximizes chances of building a sustainable and competitive companies. egcseedcapital.pl
emp Biotech GmbH
Address
Robert-Rössle-Str. 10
D-13125 Berlin
Germany
www
www.empbiotech.com
Organisation Type
Company
Contact Person
Name
Derek Levison
Position
CEO
E-Mail
[email protected]
Short Description
Quality Reagents and Services for the Life Sciences Founded in 1993 with a strong focus in organic synthesis, biomolecular modification and purification, emp BIOTECH provides
quality reagents and services for the life science community. We manufacture fine chemicals, DNA synthesis reagents, tools for molecular biology, chromatography media and
related products. In addition, we provide contract organic synthesis, protein and nucleic acid labeling, peptide synthesis, consulting and analytical services. Furthermore, we
have an ongoing interest in the fields of non-radioactive detection systems, synthetic organic and polymer chemistries and purification services. Our novel detection platforms
combine non-enzymatic chemiluminescence signal amplification and fluorescence enhancement strategies, both supported by synthetic innovations. Products and services of
emp BIOTECH include: Synthesis of fluorescent probes, linkers, haptens, modified nucleosides and nucleotides Labelling of proteins and purification of conjugates Custom
synthesis in sizes from submicrogram amounts to 200 L batch reactions Synthesis of chemiluminescent sensitizers, precursors and electron-transfer markers Distribution and
sales of reagents, kits and fine chemicals for the life sciences Manufacture and packaging of pure, high quality fine chemicals Manufacture of speciality solvents, mixtures and
reagentsr Manufacture of products for modification and or purification of DNA and proteins Manufacture of gel filtration columns, spin columns and multiwell filtration plates
EngineArch
BioPartnering
Address
Piotrkowska 76
Łódź 90-102
Poland
www
enginearch.com
Organisation Type
Company
Contact Person
Name
Marek Pietrucha
Position
Founder, CEO
E-Mail
[email protected]
Short Description
EngineArch is a web tools developer company with proficiency in Ruby on Rails platform. Our team of young professionals includes very clever and experienced programmers,
creative designers and tech-savvy, open-minded project leaders, always eager to act providing out-of-the-box solutions.
Range of our products varies from e-commerce trading platforms through community centers to complicated logistic management systems, but we don’t stop there. We are
looking forward to new challenges, ideas and suggestions.
The segment of life science with its high-tech research and development, needs tools on exact same level of proficiency. Our expertise in technological aspects for web tool
implementation can be of huge value for those, willing to get through on such a competitive market.
We are open for cooperation with companies of any background and scale. Along with creation of efficient tools we provide our customers with extensive analysis for our
products, taking into account possibilities for expansion, user experience and company marketing policy.
Eppendorf Poland Sp. z o.o.
Exhibitors #36/45, BioPartnering
Address
Al. Jerozolimskie 212
02-486 Warszawa
Poland
www
http://www.eppendorf.pl
Organisation Type
Company
Contact Person
Name
Anna Pietrzak
Position
Sales Manager
E-Mail
[email protected]
Short Description
Eppendorf is a leading life science company that develops and sells instruments, consumables and services for liquid, sample and cell handling in laboratories worldwide. Its
product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers and DNA amplification equipment as well as ultra-low
temperature freezers, fermentors, bioreactors, CO2 incubators, shakers and cell manipulation systems. Associated consumables like pipette tips, test tubes, microliter plates
and disposable bioreactors complement the instruments for highest quality workflow solutions.
Eppendorf products are most broadly used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the
chemical and food industries. They are also aimed at clinical and environmental analysis laboratories, forensics and at industrial laboratories performing process analysis,
production and quality assurance.
Eppendorf was founded in Hamburg, Germany in 1945 and has about 2,700 employees worldwide. The company has subsidiaries in 25 countries (also in Poland) and is
represented in all other markets by distributors.
ETTBio - Effective Tachnology Transfer in Biotechnology, City of Warsaw
Address
Plac Bankowy 3/5
00-950 Warszawa
Poland
www
www.ettbio.eu
Organisation Type
Other
Contact Person
Name
Karolina Niewiadomska
Position
Inspector
E-Mail
[email protected]
Short Description
ETTBio (Effective Technology Transfer in Biotechnology) aims to identify, exchange and share good practices enabling successful and effective technology transfer in
biotechnology.
ETTBio addresses the challenging issue of untapped economic potential of research institutes and universities as a source of innovation and, hence, efficient regional economic
development. The project focuses on biotechnology as the key sector, the key enabling technology in 21st century Europe. The sector ha
s very specific characteristics, which have a significant impact on a successful design of the technology transfer process. The potential of biotechnology is, however, hindered by
lack of experience and deficiencies in existing policies.
ETTBio tackles such deficiencies. The project aims to identify, exchange and share good practices enabling successful and effective technology transfer in biotechnology, and
improve local and regional policies accordingly. Improved policies can then lead to a higher number of new companies, creation of new jobs, higher tax income, as well as an
increase in the regional innovative capacity and economic performance.
In order to achieve that goal, 10 project partners from 7 Member States collect and analyse good practices in biotechnology transfers, exchange know-how on them, adapt
selected good practices to their regional contexts, and develop regional implementation plans for good practice transfer.
The project benefits from heterogeneous character of the partners: in terms of geography; level of experience in policies on technology transfer in the biotechnology sector;
and link to direct policy-making. Diversity of the partnership makes gathering of all the relevant information on the subject possible. Eventually, the partners use their findings
for concrete policy actions.
The project is co-financed by the European Union (ERDF – European Regional Development Fund) and made possible by the INTERREG IVC Programme. The project is running
from 1st January 2012 until 31st December 2014 with a total budget of 2.2 million Euro. The Interregional Cooperation Programme INTERREG IVC, financed by the European
Union’s Regional Development Fund, helps Regions of Europe work together to share experience and good practice in the areas of innovation, the knowledge economy, the
environment and risk prevention. EUR 302 million is available for project funding but, more than that, a wealth of knowledge and potential solutions are also on hand for
regional policy-makers.
Eurofins Pharma Bioanalysis Services UK Ltd
BioPartnering
Address
91 Milton Park
Abingdon, Oxon OX14 4RY
United Kingdom
Organisation Type
Company
Contact Person
Name
Andy Brown
Position
Senior Business Development Manager
E-Mail
[email protected]
Short description
Merck Millipore’s. Discovery & Development Solutions provide bioanalytical contract services to support large molecule drug development from early phase toxicology through
phase IV post-marketing studies including immunogenicity testing, pharmacokinetics, biomarker testing services and stability / batch release services to support cGMP, GLP or
GCP as relevant. Using the latest analytical platforms – Biacore, Luminex, MSD, ELISA, Gyrolab and Flow Cytometry and adhering to the most recent guidelines, we support
global studies from our UK and US locations in Oxford and St.Charles. Our experience encompasses novel biotherapeutics, biosimilars, cytokines, CD markers, proteins, receptor
occupancy assays, ligand-binding kinetics, biomarker screening and potency assays. Contact us at the CEE Bioforum to see how we can work together on your next large
molecule bioanalytical project.
GE HEALTHCARE EUROPE GMBH
Address
Zweigniederlassung Osterreich Euro Plaza - Building E Wienerbergstrasse 41 A-1120 Wien
Austria
www
www.gelifesciences.com
Organisation Type
Company
Contact Person
Name
Isabelle Henry
Position
Event Specialist
E-Mail
[email protected]
Short Description
GE Healthcare Life Sciences provides tools for drug discovery, biopharmaceutical manufacturing and cellular technologies, so research scientists and specialists around the
world can be more productive, effective, and creative. Our vision is to be the start-to-finish bioprocessing solution provider, the partner of choice in cell and protein research,
and the leader in life sciences services. Building on our broad expertise across life sciences, we are firmly committed to help researchers around the world discover new ways to
predict, diagnose and treat disease. For more information, visit our Web site at www.gelifesciences.com.
Gedeon Richter Polska Sp. z o.o.
BioPartnering
Address
Ks. J. Poniatowskiego 5
05-825 Grodzisk Mazowiecki
Poland
www
http://www.polfa-grodzisk.pl/
Organisation Type
Company
Contact Person
Name
Andrzej Ernst
Position
R&D Director
E-Mail
[email protected]
Short Description
Gedeon Richter jest jedną z wiodących firm farmaceutycznych w Europie. Od momentu założenia na Węgrzech, w roku 1901, Gedeon Richter rozwinął się do rangi
międzynarodowej korporacji. Obecnie Richter zatrudnia prawie 11 tysięcy pracowników na całym świecie. W ofercie koncernu znajdują się oryginalne i generyczne produkty
farmaceutyczne z najważniejszych obszarów terapeutycznych. Koncern stale inwestuje w rozwój swoich produktów, przeznaczając na badania i rozwój ponad 10% wartości
przychodów.
W Polsce Gedeon Richter reprezentowany jest przez dwie spółki: Gedeon Richter Polska, bazę produkcyjną i rozwojową oraz Gedeon Richter Marketing Polska, spółkę
odpowiedzialną za promocję i sprzedaż produktów Richtera w kraju.
Giełda Papierów Wartościowych w Warszawie S.A.
BioPartnering
Address
Książeca 4
00-298 Warszawa
Poland
www
www.gpw.pl
Organisation Type
Company
Contact Person
Name
Robert Kwiatkowski
Position
Deputy Director
E-Mail
[email protected]
Short Description
Warsaw Stock Exchange is the biggest securities exchange in Central and Eastern Europe. WSE organises trading on one of the most dynamically growing capital markets in
Europe. WSE operates a regulated market of shares and derivative instruments and the alternative stock market NewConnect for growing companies. WSE is developing
Catalyst, a market for issuers of corporate and municipals bonds, as well as commodity markets. Since 9 November 2010, WSE is a public company listed on Warsaw Stock
Exchange. For more information visit http://www.gpw.pl.
GLOBAL CARE Initiative
BioPartnering
Address
Institut Pasteur - 28 rue du Docteur Roux 7
5724 Paris Cedex 15
France
www
http://www.globalcare-initiative.com/
Organisation Type
Academia
Contact Person
Name
Bertrand Coulomb
Position
Head of Development Europe
E-Mail
[email protected]
Short Description
GLOBAL CARE Initiative is a non-profit consortium involving 5 French research institutes : Institut Curie, ICM (Brain & Spine Institute), Institut de la Vision, CALYM and Institut
Pasteur. These institutes have joined to expand their international research partnerships with the industry and other RTOs. Disease focused - cancer, CNS, vision and audition,
lymphoma and infectious diseases - these institutes offer the whole chain of expertise from fundamental research to clinical assesment of new therapies, diagnostics or
imaging techniques. Internationnaly recognized in their fields, they are commited to bringing innovation to the patient.
hameln rds, a.s.
Address
Horna 36
90001 Modra
Slovakia
www
www.hameln-rds.com
Organisation Type
Company & Researchorganization
Contact Person
Name
Marian Takac
Position
Vice President / Sales and Marketing
E-Mail
[email protected]
Short Description
hameln rds, a.s. is a CRO with its research and development site in Modra (Slovakia), a member of the Hameln Group (Germany), specializing in the research and development
of pharmaceuticals.
Since more than 30 years, hameln rds, a.s. offers to the clients high quality API and FDF development, laboratory services including QC and batch release, biological and
preclinical studies, including ADME/DMPK and pharmacokinetics studies, a full registration service with reliable supply of APIs and finished products. Moreover, IMP handling
activities are also very well established in the facility.
hameln rds, a.s. provides a comprehensive portfolio of services for clients from the pharmaceutical, biotechnological, chemical, cosmetics and food industries.
In addition, the company have recently started to focus on the research and development of biologics and biosimilars as a part of the successfully and rapidly growing market.
All services and studies are offered in compliance with GLP, GMP and GCP conditions respectively, and some part of the business is FDA approved.
Research and Development activities are focused on following areas:
•





API’s development and research is focused on the development and optimisation of API synthesis at the laboratory level. Moreover, the work is focused on the
development and improvement of the purification process in order to produce the final laboratory batches of API, qualification and synthesis of possible impurities
during API synthesis in order to prepare all documents required for the compilation of European DMF (Drug Master File) for the synthesised API.
Analytical development and research includes development of analytical methods in accordance for registration documentation and corresponding Pharmacopoeia.
All methods are validated according to ICH. We can provide stability testing for all dosage forms. Batch release to the European market is performed by own Qualified
Person.
Galenical development and research is focusing on the development of solid, semi-solid and liquid dosage forms as well as lyophilisates. This includes preformulation studies, development of dosage forms, production of laboratory batches and preparation of documentation required for submission and registration.
Biological research is mostly focused on development activities which require the use of different test systems (cells, in vitro systems, experimental animals, etc.).
These activities are performed as part of the development of new drugs, evaluation of drug safety, safety of chemical substances, food additives or medical devices.
Furthermore, these include evaluation of efficacy of substances at the cellular and sub-cellular level, preclinical evaluation of drug efficacy with focus on
pharmacology, pharmacokinetics and ADME, evaluation of in vivo safety of drug and its toxicity as a function of dosing and route of administration.
Biomedicinal research is focused on clinical evaluation of drug safety, at the moment mostly in the field of Bioequivalence and phase II studies.
Biosimilars are biotherapeutic products which are similar in terms of quality, safety and efficacy to an already licensed reference biotherapeutic products. hameln
rds, a.s. using the frame of the in-house running European funding projects (rh Insulin and rh Trombin) endeavours to establish the methodology for biologics (Ab
determination, ELISA methods, biological activities). Moreover the company offers batch release services along with biological studies for later compilations of
dossiers for biosimilars registration in the EU.
Institut Pasteur
BioPartnering
Address
28 rue du Docteur Roux
75015 Paris
France
www
www.pasteur.fr
Organisation Type
Academia
Contact Person
Name
Jessica Robert
Position
PhD
E-Mail
[email protected]
Short Description
The Institut Pasteur is a non-profit private foundation developing multidisciplinary approaches dedicated to the prevention, diagnosis and treatment of diseases. Research
areas include: cell biology, developmental biology, stem cells biology, genomic, genetics, immunology, epidemiology, microbiology, neurosciences, parasitology, mycology,
structural biology, chemistry, virology and oncology. These activities are sustained by 14 cutting-edge technological platforms, the Institut Pasteur International Network and
clinical research.
INSTITUTE OF INDUSTRIAL ORGANIC CHEMISTRY BRANCH PSZCZYNA
Address
Doświadczalna 27
43-200 Pszczyna
Poland
Phone
+48 32 210 30 81 ex. 114
www
www.ipo-pszczyna.pl
Organisation Type
Contact Person
Name
Lucyna Kowalczyk
Position
Planning& Marketing Specialist
E-Mail
[email protected]
Short Description
The Institute of Industrial Organic Chemistry (IPO), Branch Pszczyna is a contract research organization with more than 65 years of tradition. As a GLP-certified Institute, it
performs a wide variety of toxicological and ecotoxicological studies of plant protection products, pharmaceutical products, veterinary medicinal products, food and feed
additives, industrial chemicals, biocides and industrial wastes. The Institute is the first in Poland to hold the Statement of GLP Compliance for all offered tests. The GLP
Certificate guarantees that the studies are accepted worldwide, and their results are of great practical and scientific value.
Institute of Organic Chiemistry Polish Academy of Sciences
BioPartnering
Address
Kasprzaka 44
01-224 Warszawa
Poland
www
www.icho.edu.pl
Organisation Type
Contact Person
Name
Lech Kozerski
Position
Professor
E-Mail
[email protected]
Name
Robert Kawęcki
Position
Professor
E-Mail
[email protected]
Short Description
The Institute of Organic Chemistry of the Polish Academy of Sciences was established to advance the fundamental research in synthesis, transformations, structure and spectral
properties of organic compounds. The Institute conducts research in several broad areas: development of new synthetic methods in organic chemistry including reactions of
carbanions, nucleophilic substitution, addition and cycloaddition reactions; molecular catalysis - phase-transfer catalysis, metathesis, organocatalysis; methodology of
asymmetric synthesis; target oriented synthesis - natural products and their analogues; unconventional methods of organic synthesis:reactions under very high pressure,
microwave-promoted reactions and syntheses on a solid matrix; selected topics in supramolecular chemistry including synthesis, reactivity, structural and conformational
studies of heterocyclic and macrocyclic compounds; development of NMR methods and their applications in organic chemistry; studies of the ion-molecule reactions in the gas
phase using mass spectrometry techniques; studies of the structure and dynamics of organic compounds using NMR,MS, IR, CD and X-ray spectral methods; quantum-chemical
studies of molecular properties; Besides the basic research programs, the Institute conducts various projects related to applied organic chemistry and technology, particularly
oriented to pharmaceutical industry.
Insitute of Pharmacology, Polish Academy of Sciences
BioPartnering
Address
Smetna 12
31-343 Kraków
Poland
www
www.if-pan.krakow.pl
Organisation Type
Contact Person
Name
Tomasz Kos
Position
Research associate
E-Mail
[email protected]
Short Description
The Institute of Pharmacology, Polish Academy of Sciences is one of the leading research institution in psychopharmacology in Poland. The scientific activity is focused on the
development of new methods and novel drugs for the treatment of psychiatric and neurological diseases such as depression, schizophrenia, anxiety, addiction, Parkinson’s
disease, learning and memory dysfunctions. The main goal of the above efforts is to improve the efficacy of pharmacological treatment, investigation of pathological
mechanisms, analysis of psychiatric drugs action in animal models of human diseases. The changes induced by drugs are tested at levels of: receptor binding, second
messengers, release and metabolism of biogenic amines, behavioral responses, receptor’s density and localization, protein kinases, genes’ expression and cytokines activity.
The Institute has the status of Centre of Excellence in Neuropsychopharmacology FRAM as well as is a member of Consortium (with Jagiellonian University Medical College)
which has been awarded by Polish Minister of Science and Higher Education with the status of Leading National Research Center KNOW 2012- 2017 in medical sciences.
Currently, one of IP PAS priorities is the implementation of translational medicine in the field of psychopharmacology and the conversion of scientific discovery into real human
health improvement. In this direction a number of initiatives are taken to bring together research scientists and partners from industry to speed up the translation of medical
advances from the laboratory to clinical practice. The subject of the offer is a group of mixed dopamine and serotonin modulators. Compounds may be regarded as drug
candidates for the treatment of schizophrenia symptoms and cognitive impairment. Key facts: - Lead structures classified as multimodal agents (serotonin, dopamine receptors
ligands) - Lead structures display anti-psychotic, pro-cognitive and pro-social efficacy; the latter suggesting favorable effects on negative symptoms of psychoses Uncomplicated synthesis In vitro testing: - Compounds display high affinity for dopaminergic D2 and D3 receptors and serotoninergic 5-HT1A, 5-HT2A, 5-HT6, 5-HT7 receptors;
they were mostly classified as D2, 5-HT2A antagonists - Compounds have no affinity for M1, H1 lowering the risk of side effects related to cholinergic-, histaminergic- activity Lead structures are brain penetrant - Lead structures display acceptable CYP interaction, no toxicity (hERG) In vivo testing: - Favorable profile in tests predictive of anti-psychotic
activity: PCP-induced hyperactivity, conditioned avoidance response (CAR), prepulse inhibition (PPI), social interaction - Pro-cognitive efficacy in the novel object recognition
(NOR) test, attentional set shifting (ASST), and others suggesting an enhancement of prefrontal flexibility disturbed in schizophrenia - Activity was confirmed following oral
administration - Lead structures don’t affect ECG in guinea pigs and show lack of cardiovascular effects in rats, suggesting the lack of cardio-toxicity
J.S. Hamilton Poland S.A.
BioPartnering
Address
Chwaszczyńska 180
81-571 Gdynia
Poland
www
www.hamilton.com.pl
Organisation Type
Company
Contact Person
Name
Martyna Westa
Position
Key Account Manager
E-Mail
[email protected]
Short Description
Laboratories of J. S. Hamilton Poland S.A. offer a broad range of products and raw materials analysis for domestic and foreig n manufacturers and distributors of
pharmaceuticals and dietary supplements. As a private and independent from industry we are leaders in this field on Polish market.
Our offer covers both routine analysis procedures for manufacturer’s quality control as well as analytical services for development, implementation and validation including
transfer of analytical methods for our clients’ applications.
We offer analytical service of raw materials, excipients, active ingredients, packaging, intermediate and finished products (medicines and dietary supplements).
Offer:
Development and Validation
Our services cover development and validation of analytical methods for raw materials, packaging, active ingredients and finished products by use of chromatography,
spectroscopy, spectrometry, electrochemistry and elemental analysis, and include:
-Identification of chemical substances
-Assay
-Purity testing
-Residual solvents (OVI)
-Heavy metals testing
-Dissolution profile
-Disintegration testing
-Stability studies
-Cleaning validation, including traces of active ingredients and residual preservatives
Implementation of Analytical Methods
-Optimization of analytical methods
-Transfer of the methods.
Quality Control
-Testing according to SOP
-Certification of research results
-Testing of raw materials in compliance with EP, FP and USP
Jagiellonian University - Centre for Innovation, Technology Transfer and University Development
BioPartnering
Address
Gołębia 24
30-007 Kraków
Poland
www
www.uj.edu.pl/www.cittru.uj.edu.pl
Organisation Type
Academia
Contact Person
Name
Klaudia Polakowska
Position
Technology Transfer Officer
E-Mail
[email protected]
Short Description
Centre for Innovation, Technology Transfer and University Development (CITTRU) is a part of Jagiellonian University, whose role is to promote university research, to support
innovation and to create cooperation with the business. CITTRU main task is to offer the scientific achievements of the Jagiellonian University in the market by providing legal
protection, licensing, sale of intellectual property rights, creation of academic business, coordination of company-ordered research projects, etc. Currently promoted
technologies are mainly focused on new materials science, pharmacology, molecular diagnostics and medical technology. Inventions offered by Jagiellonian University are
promoted and awarded during numerous exhibitions, e.g. 58th and 62th International Exhibition of Innovation, Research and New Technologies INNOVA (BRUSSELS 2009,
2013), 38th International Exhibition of Invention New Techniques & Products (Geneva 2010) or 24th International exhibition of environmental equipment, technologies and
services POLLUTEC (Paris 2009) or 64th International Trade Fair Ideas Inventions New Products (Nuremberg, 2013). The current Jagiellonian University’s offer mainly includes
technological inventions in the field of new materials with a wide group of catalysts for environmental applications, as well as pharmacology, molecular diagnostics and medical
technology, inter alia: 1. Protective coating for metal implants. 2. Novel antiviral agent based on modified chitosan. 3. Modified polysaccharides for heparin removal and
neutralisation. 4. New method of prevention of diabetes complications. 5. Drug candidates for treatment of epilepsy and/or neuropathic pain. 6. Anticancer therapy based on
modified Salmonella strain. 7. New stymulant of dendritic cell migration. 8. Material for selective adsorption of nucleobases and their derivatives. 9. A new method of obtaining
chlorophyll derivatives using genetically modified bacteria. 10. Hybrid material containing silver nanoparticles. 11. New method for efficient isolation of microbial DNA from
blood. 12. New cinnamic acid derivatives in the treatment of neurological diseases. 13. Novel pharmaceutical composition in the treatment of infections and inflammation of
epithelia. 14. The use of modified Saccharomyces strains in food and cosmetic industry. 15. Identification method in the diagnosis of RNA viruses. 16. 5-HT6 receptor
antagonists for the prevention and treatment of central nervous system diseases. 17. Super paramagnetic iron oxide nanoparticles for diagnostics with NMR techniques and
fluorescence microscopy. 18. Anti-histidine Tag DNA aptamers for biotechnological applications. 19. A new PCR method for detection of bacteria and fungi in biological sample.
20. A new method for species identification and determination of phylogenetic relationships in the genus Staphylococcus. 21. A diagnostic test of Streptococcus agalactiae
infections in pregnant womens. 22. A new method for purification of PCNA recombinant human protein without a fusion tag. 23. New amide derivatives of aminoalkanols in
the treatment of neurological diseases.
JWP PATENT & TRADEMARK ATTORNEYS
BioPartnering
Address
Zelazna 28/30
00-833 Warszawa
Poland
www
http://www.jwp.pl/
Organisation Type
Company
Contact Person
Name
Miroslawa Wazynska
Position
Polish & european patent attorney
E-Mail
[email protected]
Short Description
JWP Patent & Trademark Attorneys (JWP) is one of Poland’s leading intellectual property law firms. JWP is a full-service firm, assisting local and international businesses in
protecting their industrial and intellectual property, whether it be trademarks, industrial designs, inventions, utility models, geographical indications, internet domain names,
copyrights or business names. JWP offers full range of IP protection services related to filling, prosecution and litigation in Poland and Europe. JWP IP litigation services involve
both handling trademark and patent infringement, unfair competition and anti-counterfeiting proceedings. JWP also offers professional advice on IP searches, valuations,
licensing, agreements and know-how transfers. JWP team is composed of experienced Polish and European patent and trademark attorneys, attorneys at law and consultants
who offer their integrated and comprehensive technical and legal expertise in IP protection and litigation. JWP has been assisting over 5000 domestic and foreign clients, and
has particularly vast experience in life-science, biotechnology, chemistry, pharmacy and cosmetic sectors, assisting Polish and international firms, R&D centres and independent
inventors. Since 2012 the firm has been operating within the JWP Group composed of 3 entities: JWP Patent & Trade Mark Attorneys (IP Prosecution & Contentious), JWP
Attorneys at Law (IP Litigation & Legal Advice), JWP Foundation (IP Education/Training & pro bono actions). Today, the group provides a unique combination of legal, advisory
and training services focused on strategic IP business management. JWP Patent & Trade Mark Attorneys Ul. Zelazna 28/30 00-833 Warsaw Poland T: +48 22 436 05 07 F: +48 22
436 05 02 W: www.jwp.pl
KCR S.A.
Address
Postępu 6
02-676 Warszawa
Poland
www
http://kcrcro.com/
Organisation Type
Company
Contact Person
Name
Joanna Lewandowska
Position
PR and Marketing Manager
E-Mail
[email protected]
Short Description
KCR is a European Contract Research Organization (CRO) and a strategic solutions provider for companies who are looking for a reliable alternative to global CROs. Almost 300
professionals operating across 18 countries in Europe as well as the U.S. offer full service capabilities for Phase I-IV Clinical Development Projects across a wide range of
therapeutic areas. KCR also operates as a Functional Service Provider with strategic and tactical solutions in Clinical Operations, Data Management and Expert Sourcing. Our
service portfolio includes delivery of regional and local Post-Marketing Clinical Services according to the clients’ needs. KCR supports 12 of the Top 20 Global Pharma companies
with its services on long standing global or local contracts. For more information please visit: www.kcrcro.com.
Komtur Polska Sp. z o.o.
Address
Puławska 405a
02-801 Warszawa
Poland
www
www.komtur.com
Organisation Type
Company
Contact Person
Name
Paweł Derwiński
Position
Public Tenders&Marketing Specialist
E-Mail
[email protected]
Short Description
Komtur Polska sp. z o.o. was established in 2004 in Warsaw as a part of Komtur Pharmaceuticals Group - one of the world’s leading providers of integrated procurement
services for pharmaceutical products. Since then our company has been a reliable partner in the distribution of drugs for clinical research. Our clients in the industry are leading
manufacturers, research organizations and packaging specialists in the area of study
drugs. As a comprehensive service provider for clinical trials, we offer the following services:
• Independent market analyses, pricing research and feasibility studies prior to planned trias.
• Supply of reference products, emergency, supplementary and background medications, and medical devices.
• Procurement of drug samples to be used in research for use in small quantities.
• Supply scenarios tailored to trial requirements and project terms defined by the customer, backed by general, service and supply agreements.
• Secure supply chains in terms of product availability, certified suppliers, product identity and continua ous recall monitoring.
• Temperature control for shipments and storage worldwide adhering to GDP and GMP standards using active and passive cooling systems; in the case of clinical trial
supplies documentation is an integral part of the contrach.
• Option to negotiate special production and documentation (CofA, MSDS, CoC etc.) on the basis of a network of contacts with various manufacturers and stakeholders.
Komtur Polska Sp. z o.o. offers option of a clinical distribution service and special distribution projects – we are the leading Polish ultra-orphan drugs distributor for such
companies like: Actelion Pharmaceuticals, Bio-Marin Pharmaceuticals, Celgene, Orphan Europe, Swedish Orphan, Shire HGT. One of our main projects is CEE Center of Logistics
for Clinical Trials in Warsaw (new facility project under construction).
KONDRAT IP LAW
BioPartnering
Address
Staropolska 26
03-289 Warsaw
Poland
www
www.kondrat.pl
Organisation Type
Company
Contact Person
Name
Mariusz Kondrat
Position
European Patent & Trademark Attorney
E-Mail
[email protected]
Short Description
KONDRAT LAW and PATENT provides services related to IP and pharmaceutical law. Our team of patent attorneys, advocates and legal advisers is helping clients with all
lifescience, trademarks and patent problems.
LABNATEK
Address
Marszałkowska 80
00-517 Warszawa
Poland
www
www.labnatek.pl
Organisation Type
Company
Contact Person
Name
Grzegorz Kaszyński
Position
Owner
E-Mail
[email protected]
Short Description
LABNATEK company was founded in 2007 as NT-MDT ( www.ntmdt.com ) distributorship in Poland. From that day our main focus was nanotechnology and related
measurement techniques. We are dedicated to provide best solutions for nanotechnology labs in Poland with our offer of the highest resolution AFM, Raman and
nanoindentation equipment. With nanotechnology market going fast from physics, materials science to biotechnology and medicine we work hard to help new users to adapt
the technology to their applications. With 7 years of experience on the market we provide our users complete solutions for their applications: high-tech devices, consumables,
laboratory equipment and after sales support and service. In most recent development LABNATEK company signed distributorship agreement with Izon Science. Izon qNano is a
new kind of particle counter that will change the nano medicine and biotechnology world forever. qNano provides ease of use combined with very high resolution
measurements of particle size, zeta potential and concentrations. With detection range from 40 nm to 10 um it is very well suited for most bio applications and costs only a
fraction of the price of laser based detection systems.
Lipopharm.pl Wojciech Kamysz
Address
Kościelna 16a
83-210 Zblewo
Poland
www
http://www.lipopharm.pl/
Organisation Type
Company
Contact Person
Name
Daria Grzywacz
Position
Head Office
E-Mail
[email protected]
Short Description
LIPOPHARM.PL Contact details: ul. Koscielna 16A 83-210 Zblewo Telephone number: +48 697 422 366 e-mail: [email protected] http://www.lipopharm.pl/ Founding year:
2006 Person to contact: Wojciech Kamysz – Director Telephone number: +48 697 422 366 e-mail: [email protected] Main activity: Lipopharm.pl specializes in the design and
synthesis of biologically active compounds possessing mainly antimicrobial activity (peptide antibiotics, disinfectants). We also take part in counseling covering the design of
peptide synthesis on laboratory and semi-industrial scale. Main products and services We offer fast synthesis of high quality compounds at relatively low cost. We mainly
specialize in the synthesis of difficult peptide sequences (peptides with Met, Cys, Trp, cyclic peptides, peptide libraries) and lipopetides. Eac h peptide is supplied with gradient
HPLC chromatogram (or TLC chromatogram in case of lipopetides) and mass spectrum. Microbiological laboratory is suitable for fast tests using reference strains available at
our laboratory. Our diagnostic offer is aimed mainly at scientific groups working on new antibacterial and antifungal substances. Research & Development activity Research
field of Lipopharm involves designing new procedures for synthesis and separation of chemical compounds as well as carrying out conformational studies on peptides. The
collaboration with pharmaceutical industry is focused on search of new antimicrobial and anticancer peptides. While the goal of co-operation with other external partners is to
obtain new microbial resistant materials that contain antimicrobial peptides.
MABION SA
Address
Józefów 9
99-300 Kutno
Poland
www
www.mabion.eu
Organisation Type
Company
Contact Person
Name
Magdalena Matusiak
Position
Pharmacologist
E-Mail
[email protected]
Short Description
Mabion SA is a leading Polish biotechnology company which has been established to introduce to the market the latest generation of drugs based on a recombinant proteins,
specially humanized monoclonal antibodies.
This technology, self-developed in Mabion, is a high-tech on the highest world level. The process of humanization of monoclonal antibodies, which is the topmost achievement
in the present biotechnology, enables production of targeted drugs that act specifically resulting in better effectiveness and lower toxicity of the therapy.
Mabion has been established in March 2007 by four domestic pharmaceutical companies: Celon Pharma from Łomianki, one of the leading manufacturer of oncology drugs in
Poland, Polfarmex from Kutno , which is the national leader on the market of prescription drug, IBSS Biomed form Kraków, the biggest in Poland and significant in Europe
manufacturer of vaccines, Genexo from Warszawa, working on the market of medical drugs and products, mainly in the field of diabetology. Mabion was also founded by two
companies focused on biotechnological research and development: BioCentrum i Biotech Consulting.
Over the past few years Mabion has gained the ability to produce free-form of biotechnology drugs starting from design step, throught the selection of a manufacturing
platform and technology, to obtaining the final product. Currently in its laboratory in Łódź the company is working on research and develo pment of several biotechnology drugs
applied in the treatment of cancer and metabolic disorders.
R&D Projects:
Currently, there are four internal projects running simultaneously. All of the projects are biosimilar therapeutic antibodies. The areas of interest are cancers and autoimmune
diseases. The first therapeutic monoclonal antibody: MabionCD20 biosimilar to MabThera is used to treat lymphomas, leukemias as well as rheumatoid arthritis. Drug
successfully passed process development and preclinical phases. Product is currently under clinical
development. The second monoclonal antibody is Mabion HER2 biosimilar to Herceptin that is used for breast cancer is under process and analytical tools development.
MabionVEGF biosimilar to Avastin and Mabion EGFR biosimilar to Erbitux are under process development.
Mabion offers contract development of other recombinant poteins, among them insulins and insulin analogs,‚from scratch’ to ready GMP product .
Marshal's Office of the Lodzkie Region
Exhibitors # 56,57, BioPartnering
Address
al. Piłsudskiego 8
90-051 Łódź
Poland
www
www.lodzkie.pl
Organisation Type
local government
Contact Person
Name
Ewa Florczyk
Position
Director
E-Mail
[email protected]
Short Description
Marshal of the Lodzkie Region: Witold Stępień Area: 18,219 sq km Population: 2.5 million people Population density: 140 people per sq km Economically active: 1.6 million
people Capital of the Region: Lodz Number of districts: 24 Number of cities with districts status: 3 (Lodz, Piotrkow Trybunalski, Skierniewice) Number of communes: 177 Gross
Regional Product (2012): ca. 22 billion EUR Number of companies (2013): 237,000 Average monthly gross wage (2013): ca. 815 EUR Regional budget, projected (2013)
Revenues: 854,8 million PLN Expenditures: 895,9 million PLN Average monthly wage (2013): ca. 830 EUR Unemployment rate (2013): 13.9% Exports (2012): ca. 3,8 billion EUR
Imports (2012): ca. 6 billion EUR Natural resources: brown coal, kaolin clays, gypsum, limestone, marl, gravel, clay, thermal waters, quartz and foundry sands, travertine
Number of students: 110,000 Number of higher education institutions: 27, including 21 private Selected higher education institutions: • the Lodz University, • the Technical
University of Lodz, • the Medical University, • National Higher School of Film, Tv and Theatre in Lodz • Academy of Fine Arts • Academy of Music • the School of Arts and
Design in Lodz Industrial and Technological Parks: • The Belchatow and Kleszczow Park of Industry and Technology, • The Kutno Park of Agriculture and Industry, • The Lodz
Regional Park of Science and Technology, • The Boruta-Zgierz Park of Industry. International Airport: the Wladysław Reymont Airport in Lodz The Lodzkie Region (Lodzkie
Voivodship) is located in the centre of Poland and Europe alike, and boasts a long tradition of textile and clothing industry. Currently, the voivodship’s capital and the third
largest Poland’s city, Lodz, is rapidly expanding its other branches of industry, including household appliances production and biotechnology. It should be added, too, that it was
thanks to foreign investment that Europe’s largest industrial cluster producing household appliances was developed in the region. Production of ceramic tiles and packagin g
have the leading position in Poland in terms of quality and quantity. Agriculture has been growing in significance, too, including organic farming, and agricultural and food
processing which was included in the long-term innovation strategy for the region. In April 2013, the Regional Innovation Strategy for the Lodzkie Region LORIS 2030 has
identified leading branches that have the greatest potential for further long-term economic development of the region. These are: • modern textiles and fashion (including
design); • advanced building materials; • medicine, pharmacy, cosmetics; • energy, including renewable energy sources; • innovative agriculture and food processing; •
information technology and telecommunications. With 42 towns and cities inhabited by 65% of the region’s population, the Lodz kie Region is also proud of its high urbanisation
rate.
Medical University of Białystok
BioPartnering
Address
ul. Jana Kilińskiego 1
15-089 Białystok
Poland
www
www.umb.edu.pl
Organisation Type
Academia
Contact Person
Name
Andrzej Małkowski
Position
Commercialization Manager
E-Mail
[email protected]
Short Description
The Medical University of Bialystok is a prestigious and distinct centre of excellence and potential. The University offers high standard of research and teaching and are an
opinion-forming milieu in the region. The ratio of over 200 professors and to 800 university teachers is one of the highest and earns the University one of the top places in the
tertiary education rankings in Poland. A total of 4500 students are enrolled in fourteen courses, including over 200 students taught in English. The learning opportunities are
being constantly enhanced to suit the needs of the continuously developing job market. The University has at its disposal the state-of-the-art research infrastructure: Centre of
Experimental Medicine, Euroregional Pharmacy Centre and Centre of Innovative Research. In July 2012, the Centre for Innovative Research of the Medical University of
Bialystok was awarded the status of the Leading National Research Centre 2012-2017 (Krajowy Naukowy Ośrodek Wiodący - KNOW). UMB scientific activities covers all areas of
medical science. Special focus is put on the search for new markers for early detection of civilization diseases and search for individualized targeted therapy of these diseases.
Innovative high-throughput technologies like: genomics, transcriptomics, epigenomics, proteomics, metabolomics and modern methods of medical imaging are in use. Medical
University of Bialystok holds scientific contacts with renowned foreign institutions, including: Mayo Clinic, National Institute of Health in Bethesda, Harvard Medical School,
University of Pennsylvania. UMB has also experience in cooperation with the business and entrepreneurs. UMB has both technologies protected by industrial property rights
ready for commercialization, as well as the know how that is the subject of commercialization. The University actively encourages its academics to take part in collaborations,
and provides support at all stages of the necessary interactions. Many collaborations are interdisciplinary, or multidisciplinary, and all relationships are bespoke. Assistance is
offered within the University by dedicated business development professionals, to help facilitate the necessary relationships, and to conduct contractual negotiations
pragmatically and efficiently. The University welcomes the opportunity to build strategic alliances or institutes with companies.
Medical University of Lodz
Address
al. Kościuszki 4
90-419 Łódź
Poland
www
www.umed.pl, www.harc.umed.pl
Organisation Type
Academia
Contact Person
Name
Mikołaj Gurdała
Position
Director of Research, Strategies and Development Office
E-Mail
[email protected]
Short Description
The Medical University of Lodz (MUL) is one of the biggest State Medical University in Poland with more than 60 years of academic tradition.
The teaching, research and clinical structure of the University comprises the following faculties:
• Faculty of Medicine with the Division of Dentistry.
• Faculty of Pharmacy.
• Faculty of Health Sciences, with the Division of Nursing and Midwifery.
• Faculty of Biomedical Sciences and Postgraduate Training.
• Faculty of Military Medicine, with the Division of Physiotherapy.
and:
• 4 teaching hospitals.
• 77 Departments.
The University employs almost 1,600 research and didactic staff, including over 300 independent researchers, i.e. 170 full professors, 190 assistant and associate professors as
well as nearly 900 PhD academics. Our educational programs arouse great interest among both Polish and international students.
Currently, over 8,000 Polish students are receiving their education within medical and medicine-related areas at various faculties. Our education offer also comprises advanced
studies at the Faculty of Postgraduate Training with over 300 postgraduate students commencing their education each year. Medical teaching in English was initiated in
2003/2004. Presently ca 300 foreign students from various countries (USA, Canada, Taiwan,
Sweden, Norway, Great Britain, Spain, Kenia, Nigeria, Zambia) attend medical and dental courses.
R&D Projects:
The Medical University of Lodz is one of the leading medical research centers in Poland. In one academic year over a hundred research grants are awarded, as well as numerous
research contracts. At present over 300 individual research projects are being conducted, of which over 100 are new ones and more than 200 are continued.
The International Research Programmes team collaborates with MUL researchers, local enterprises and any international units and organisations that are interested in research
cooperation, with special regard to the EU 7.
Framework and Public Health Programmes. As of December 2011, MUL research teams have participated in 26 projects co-financed by the European Commission, with 13
ongoing projects and 1 project currently in the stage of negotiations. At present, MUL is coordinating one Cooperation Project: Ascertaining Barriers for Compliance:
policies for safe, effective and cost-effective use of medicines in Europe (ABC).
The Medical University of Lodz has been carrying an extensive international scientific cooperation with such foreign academic and research centers as:
• MD Anderson Cancer Center (MDACC) USA.
• Institute of Biomedical Engineering CNR; Italy.
• Universite de Geneve, Switzerland.
• Academic Medical Center by the University of Amsterdam, The Netherlands.
• King’s College London, United Kingdom.
• University of Alabama at Birmingham (UAB).
Within this co-operation over 500 short official visits of research and teaching staff to 46 universities took place, 22 staff members received foreign scholarships and 49 foreign
scientists representing leading European and world-famous teaching and research centers were invited to our University. Furthermore, the majority of University chairs, clinics
and departments directly co-operate with foreign centers through staff exchange programs (workshops).
Medical University of Warsaw, BASTION project
BioPartnering
Address
Zwirki i Wigury 61
02-091 Warsaw
Poland
www
www.wum.edu.pl, www.bastion.wum.edu.pl
Organisation Type
Academia
Contact Person
Name
Karolina Dzwonek
Position
Innovation Manager
E-Mail
[email protected]
Short Description
The Medical University of Warsaw is one of the oldest medical schools in Poland. For over 200 years it has provided education and training in medicine and pharmacy at
undergraduate and postgraduate levels. The university's programs meet the highest international standards of university-level education and are based on the principles of
good clinical and pharmaceutical practice. BASTION (From Basic to Translational Research in Oncology) is a multidisciplinary project financed by European Commission under
7th Frame Programme. Its primary objective is to facilitate transition from scientific discovery to clinical application in oncology. The project brings together highly skilled and
complementary assembly of European researchers integrating and strengthening cancer research within the European Research Area. It involves 10 research teams of Medical
University of Warsaw, represented by more than 100 researchers, and 10 partnering institutes from all over Europe. The research program is envisaged to have a long-lasting
and direct impact on survival and quality-of-life of cancer patients through the provision of more tailored and effective diagnostic and therapeutic strategies. It is our priority to
make best practice in science - industry cooperation and to facilitate innovation driven translational research. To make a success, a coordinated, cross-European, multidisciplinary effort is needed.
MediScience - a regional CRO company.
Address
Chorągwi Pancernej 50
02-951 Warsaw
Poland
www
http://www.mediscience-net.com/
Organisation Type
Company & Research_organization
Contact Person
Name
Magda Zbrzeźniak
Position
Strategy & Innovation Leader
E-Mail
[email protected]
Short Description
Mediscience. Art of Research in Expert Hands Mediscience Network Adress: Hlonda Str. 4F/3; 02-972 Warsaw, Poland Phone: +48 22 121 78 08; Fax: +48 22 126 78 58 Website:
www.mediscience-net.com E-mail: [email protected] Mediscience is a regional clinical research organization (CRO), located in Poland and Romania. We are a team of
experts with diverse knowledge and years of experience on complex projects in multiple therapy areas, ready to answer the nee ds of partners who: - Demand clinical research
project to be completed according to the highest State - of - the -Art GCP standards - Intend to cooperate with experts, who have a professional overlook of the whole project,
and personally attend to clinical operations Start partnering with us for a broad range of services in the area of clinical research: - Project Management - Site Management &
Monitoring - Quality Audits - GCP training For more information visit us at www.mediscience-net.com We invite you to contact us directly: Magda Zbrzeźniak Strategy &
Innovation Leader Mobile: (+48) 885 818 828 E-mail: [email protected]
Merck Sp. z o.o.
Address
Merck Sp. z o.o. Jutrzenki 137
02-231 Warszawa
Poland
www
www.merckmillipore.pl
Organisation Type
Company
Contact Person
Name
Katarzyna Mamzerowska-Kucharska
Position
Key Account Manager Pharma
E-Mail
[email protected]
Short Description
Merck Millipore provides technologies, tools and solutions that enable customers to achieve success in the areas of life science research and biotech and pharmaceutical
manufacturing. It offers more than 60,000 products across three Business Areas and is a top-tier supplier of tools to the life science industry—serving as a strategic partner for
scientists, engineers and researchers worldwide. Merck Millipore is a division of Merck, a global pharmaceutical and chemical company based in Darmstadt, Germany, with
total revenues of €11.1 billion (2013). The division, known as EMD Millipore in the United States and Canada, is headquartered in Billerica, Massachusetts, and employs nearly
10,000 people in 66 countries.
MTZ Clinical Research Sp. z o.o.
Address
Pawińskiego 5
02-106 Warsaw
Poland
www
www.mtz-clinical.pl
Organisation Type
Company
Contact Person
Name
Marta Zakrzewska
Position
Marketing Specialist
E-Mail
[email protected]
Short Description
MTZ Clinical Research Sp. Z o.o. Is a leading Polish company. MTZ has been operating since 2002 and specializes in early-phase clinical studies. MTZ has its own Site with an
intensive care room, registered medical analysis laboratory, laboratory for biological sample processing and a registered pharmacy for study products, including oncological
products.
NanoVelos Sp. z o.o.
Address
Waryńskiego 1 room 415
00-645 Warszawa
Poland
www
www.nanovelos.com
Organisation Type
Company
Contact Person
Name
Dariusz Smoleń
Position
CEO
E-Mail
[email protected]
Short Description
NanoVelos is a biotechnological start-up set up by Professor Tomasz Ciach from the Warsaw University of Technology, Faculty of Chemical and Process Engineering and by
Polish-Israeli VC fund GIZA Polish Ventures. NanoVelos is developing a unique drug delivery platform made of polysaccharide nanoparticles for anticancer drugs delivery.
NanoVelos nanoparticles provide precise drug delivery with fully controlled release. As research showed application of known anticancer drugs encapsulated in NanoVelos
nanoparticles radically improves therapy efficiency and decrease side effects.
TECHNOLOGY
The production process is based on the polysaccharide chains self-assembly phenomenon without use of any toxic materials or metal particles. It allows to form the
nanometrical sphere with polysaccharide frame outside and all drug molecules inside.
ADVANTAGES
The NanoVelos' particles are fully biodegradable. In comparison to currently known and investigated solutions are stable, can circulate in the vascular system for a long time
and does not cause blood plasma protein aggregation. The particle is in a form of hydrogel which prevents interactions with proteins and inflammatory system response.
The main competitive advantage of the NanoVelos technology is utilization of Warburg effect for targeted anticancer therapy. Cancer cells in comparison to original cells have
about 200 times higher demand for glucose. NanoVelos particles outside layer is made of polysaccharide (the drug is encapsulated inside particle) which makes them an
"attractive" source of energy for cancer. By the Warburg effect utilization the cancer cells are actively targeted by NanoVelos nanoparticles carrying anticancer drugs inside.
What’s more, the NanoVelos nanoparticles structure allows significantly reduce anticancer therapy side effects. Fast drug release is possible only after getting to the targeted
cancer cell.
APPLICATIONS
NanoVelos drug delivery platform dedicated to anticancer drugs targeted delivery. The NanoVelos first product is doxorubicin encapsulated in NanoVelos nanoparticles. As in
vivo trials proved the application of NanoVelos technology for doxorubicin administration improves its accumulation in tumour by over 5 times with almost no side effects
comparing to the classical doxorubicin therapy.
For more details please visit our website (www.nanovelos.com) or contact with us directly via mail: [email protected].
Patpol Kancelaria Patentowa Sp. z o.o.
Address
Nowoursynowska 162 J
02-776 Warszawa
Poland
www
www.patpol.pl
Organisation Type
Company
Contact Person
Name
Karolina Oświęcimska
Position
Koodynator ds. Marketing i PR
E-Mail
[email protected]
Short Description
With more than 45 years in business, PATPOL is one of the leading firms in the field of intellectual property in Poland and Europe. With this extensive experience we are able to
provide our clients from all over the world with the highest quality full service in all matters relating to IP. PATPOL employs experts representing various fields of technology.
This includes patent, trademark and design attorneys as well as lawyers providing advice on IP rights enforcement, litigation, domain names disputes, and other matters
required for businesses to protect and exploit their IP assets. Our practice is entirely dedicated to patents, trademarks, designs, utility models, domain names and IP-related
disciplines. In addition, our professional staff of patent, trademark and design attorneys, lawyers, engineers and translators are technically trained subject matter experts in
various fields of technology, as well as experts in IP law. PATPOL's services include: Protection of patents, trademarks, utility models, designs and domain names Searches and
opinions on patent, trademark and industrial design availability, registrability or validity Monitoring of patents and trademarks IP litigation in the administrative, civil and
criminal courts Border measures, anti-counterfeiting and enforcement of IP rights Unfair competition cases We represent clients before the Polish Patent Office, European
Patent Office, and Office of Harmonization for the Internal Market (OHIM), World Intellectual Property Organization (WIPO), Polish Courts and Customs Authority. Patpol 162J
Nowoursynowska Street 02-776 Warsaw, Poland Phone: +48 22 644 96 57
PerkinElmer Polska Sp. z o.o.
Address
ul. Wołoska 9
02-583 Warszawa
Poland
www
www.perkinelmer.com
Organisation Type
Company
Contact Person
Name
Andrzej Kasprzak
Position
Sales Specialist
E-Mail
[email protected]
Short Description
Backed by an outstanding team of 7,600 employees and located in over 150 countries across the world, PerkinElmer is a global leader focused on improving human and
environmental health, for the better. We provide our customers with critical knowledge, expertise and innovative detection, imaging, software, and services solutions so that
they can make better decisions for better outcomes. At PerkinElmer, we make a difference everyday – helping scientists, clinicians and governments detect earlier and more
accurately to improve the health and safety of people and the environment. Our solutions range from enabling the discovery of more effective diagnostics and therapies, to
making sure that the food we eat, the water we drink, and our environment are safe from contaminants. PerkinElmer conducts business in nearly every country across the
globe. In addition to providing extensive knowledge and expertise and leading capabilities, we are committed to delivering a consistent customer experience around the globe,
exemplifying quality, personable, knowledgeable and responsive service and support.
Pharmnet, s.r.o.
BioPartnering
Address
Peckova 13
186 00 Prague 8
Czech Republic
www
www.pharmnet.cz
Organisation Type
Company
Contact Person
Name
Zuzana Elbertova
Position
Business development manager
E-Mail
[email protected]
Short Description
PHARMNET, s.r.o. is an independent CRO located in Prague, Czech Republic. Founded in 1994, it has conducted more than 200 clinical studies in Central Europe, especially in
the Czech and Slovak Republic. The PHARMNET team consists of office based physicians and doctorate level professionals with average of 5 years of experience in clinical trials
field. Our intimate knowledge of local milieu allows us to establish extensive network of investigators in any medical field in considerably short time and rescue projects
suffering from slow recruitment rate. International trials requiring extensive recruitment and/or coverage of specific countries are organized jointly with the AcrossAlliance
partners with the support of project management tools developed for that purpose and certified to ISO 9001:2000 by TÜV (Certificate No.01 100 061453/07). Our lead Project
Managers are IPMA certified and use sophisticated internally developed software tools allowing a fast tracking of all trial activities and keeping the audit trail. Our services
comprehend: Medical and protocol writing (English, Czech) CRF development Project management Regulatory submission Qualified translation of study documents to Czech or
Slovak Study site selection Investigator and hospital grant negotiation and management Investigators’ meeting organization Site initiation and monitoring Clinical supplies
accountability Audits, compliance monitoring visits, system audits (in Czech, Slovak, English and Russian) e-CRF, DM, statistics (in collaboration with our AcrossAlliance partner:
ICTA PM, Dijon, France) Medical devices investigations Our client base are pharmaceutical and biotech companies seeking fast recruitment rate and outstanding quality for
reasonable price, as well as foreign CROs seeking a task-specific support in Czech or Slovakia. 5 Reasons why to choose us: 1. We have experience On the european market
since 1994, over 200 clinical trials completed. 2. It´s all about quality 75% of repeated business. 3. Full service Full service for all phases of clinical drug development and
medical devices. 4. Time adherence 88% of projects reached target recruitment on time. 5. Communication is the key Providing fast performance feedback to our clients.
Politechnika Gdańska
BioPartnering
Address
G. Narutowicza 11/12
80-233, Gdańsk
Poland
www
www.pg.gda.pl
Organisation Type
Academia
Contact Person
Name
Grzegorz Gorczyca
Position
Broker Innowacji
E-Mail
[email protected]
Short description
The Gdansk University of Technology is a large community – almost one thousand two hundred academic teachers, more than twenty‐one thousand students, around one
thousand four hundred engineering, technical and administrative staff, and over seventeen hundred retired employees with whom the University remains in touch. Our
community is therefore vibrant with life. The Gdansk University of Technology enjoys a prominent position as a modern place of learning. It is highly regarded as an opinion‐
forming centre and as the initiator, and reliable executor, of a wide range of undertakings as well as innovative tasks. Our success is measured by the great number of
achievements in research, teaching and implementations. The Faculty of Chemistry plays a leading role in the life of the University. Research at FC is focused on the most
challenging topics of modern chemistry and chemistry-related scientific areas, including: supramolecular, bioorganic and bioinorganic chemistry, methods of chemo- and
bioanalysis and monitoring of environment, green chemistry and technology, design, construction and evaluation of synthetic drug candidates and biopharmaceuticals,
functional polymers, electrochemistry and corrosion science, renewable energy, functional food technology, separation technologies, construction of recombinant proteins for
industrial biocatalysis or medical diagnosis, investigation of structural and functional properties of biomacromolecules. Research activity and scientific achievements of the
academic staff constitute a solid basis for education of students, who gain knowledge and the practical skills at the BSc, MSc or PhD level in a variety of curricula, including
Chemistry, Chemical Technology, Biotechnology, Environmental Protection and Management (at BSc level taught exclusively in English) and Material Engineering.
Polska Biotech & Pharma
Address
Dąbrowskiego 84 B m 21
02-571 Warszawa
Poland
www
biotech-pharma.pl
Organisation Type
Company
Contact Person
Name
Maciej Zaleski
Position
Biotech & Pharma Project Leader
E-Mail
[email protected]
Short description
Polish Biotech & Pharma is a Sector Promotion Programme under the system project implemented by the Polish Ministry of Economy entitled: “The Promotion of Polish
Economy on International Markets”, Sub-measure 6.5.1 of the Innovative Economy Operation Programme. The programme aims at supporting individual entrepreneurs in a
variety of promotional events and international expansion, which contributes to building a strong brand of Polish biotech and pharmaceutical industries. It includes diverse
forms of promotion, such as participation in international fairs, trade missions, conferences, foreign press study visits, investors study visits, and matchmaking meetings (B2B).
These activities are supported by a professional advisory service and a series of specialized trainings in foreign trade and registration of products in foreign markets. Scheduled
events will take place in different countries, mainly in Germany, USA, Russia, China, Switzerland and Spain. Sector Promotion Programme Polish Biotech & Pharma allows a
direct promotion of Polish companies and it is an opportunity to obtain prospective business partners among the leading companies from the biotechnology and
pharmaceutical industries. The project is implemented by the consortium of companies Ageron Polska and Ageron Internacional. We will be pleased to assist you with any
questions concerning the Polish biotechnology and pharmaceutical companies.
Pomeranian Science & Technology Park Gdynia
BioPartnering
Address
al. Zwycięstwa 96/98
81-451 Gdynia
Poland
Contact Person
Name
Matylda Sidwa - Gorycka
Position
Laboratory Manager of Pomeranian Science and Technology Park Gdynia
E-Mail
[email protected]
Short Description
Sales, service and distribution of laboratory instruments, Ultra Low Temperature freezers, and other.
R&D Projects:
The PSTP Laboratory is experienced in:
• Mass spectrometry (mass measurement of biological molecules, identification of samples peptides mixture LC MS/MS.
• Methods of recombinant protein isolation and purification.
• Gene cloning to expression systems.
• DNA sequencing, PCR amplification.
• Plant cultures in vitro.
PPHU GENOS s.c.
Exhibitors #48, BioPartneing
Address
Inowrocławska 9/132
91-020 Łódź
Poland
www
www.genos.com.pl
Organisation Type
Company
Contact Person
Name
Agata Wyrębska
Position
sales and marketing
E-Mail
[email protected]
Short Description
Genos consists of Genetic Outpatient Clinic with Laboratory and trade office. The GENOS Non-Public Outpatient Clinic with Laboratory provides specialist counselling and
diagnosis in clinical genetics, including prenatal diagnostics, reproduction failure, marital infertility, high risk pregnancy management and genetic prophylactics and diagnostics
of predispositions to selected neoplastic diseases. At the GENOS trade office, you can find necessary reagents, media, small plastic laboratory accessories and equipment for
cell culture.
Proteon Pharmaceuticals S.A.
Address
Tylna 3a
90-364 Łódź
Poland
www
www.proteonpharma.com
Organisation Type
Company
Contact Person
Name
Justyna Andrysiak
Position
R&D Project Manager
E-Mail
[email protected]
Short Description
Proteon Pharmaceuticals is a biotechnology company operating in the field of animal health. The company originated as a research spinoff, commercializing a novel technology
for in vitro tests of biological activity. In 2009 Proteon Pharmaceuticals began to focus on developing a new generation of antibacterial agents based on bacteriophages. The
bacteriophages developed by Proteon offer a promising solution to a global animal farming problem: namely the presence of Salmonella in industrially-farmed chickens.
Pure Biologics Sp. z o.o.
Address
ul. Duńska 9
54-427 Wrocław
Poland
www
http://www.PureBiologics.com/
Organisation Type
Company
Contact Person
Name
Filip Jeleń
Position
CEO
E-Mail
[email protected]
Short Description
Pure Biologics has commercialized technologically-advanced platforms for recombinant protein production and purification, as well as proprietary methods for the selection of
recombinant antibodies, for biomedical and diagnostic use. The company’s technologies are supported by extensive R&D activities and the unique in-house expertise and
know-how of the company.
PureSelect™ - A human recombinant monoclonal antibody selection platform against custom molecular targets, including whole cells. Currently, most antibodies used in
biomedical research and biotherapeutic applications are obtained by in vivo immunization of animals and subsequent selection utilizing hybridoma screening technology. The
antibodies obtained in this way need to be further ‘humanized’ in order to be safely used in clinical studies. Our technology allows for in vitro selection of high-affinity human
recombinant antibodies against practically any custom antigen, including whole-cell immunization, without the need for subsequent humanization. Finally, the selected
antibody fragments can be converted (using recombinant DNA technology) into the other antibody formats, including: full IgG molecule, Fab or scFv dimer, and further
chemically functionalized to give rise to a drug lead candidate, for example, an antibody drug conjugate (ADC), or molecular diagnostic tool, such as a fluorescent labeled
probe.
PurePerformance™ - A recombinant protein production capability that delivers high bioequivalence. The company provides a complete gene-to-protein service. Starting from
sequence optimization and vector construction, through biomass production to delivering pure protein products.
PureFold™ - Pure Biologics has a proven track-record for successfully producing proteins with high bioequivalence. Additionally, it offers its own high-throughput screening
platform utilizing proprietary conditions for successful refolding of proteins from inclusion bodies, to give rise to biologically active macromolecules.
PureAnalytics™ - As part of the company’s focus on product quality and biological function, Pure Biologics offers a comprehensive range of bioanalytical protein
characterization methods, including MS, MS/MS, DLS, CD, SEC, DSC, Biacore/SPR and ELISA. The company is therefore uniquely positioned to be able to offer its clients an
unparalleled service with respect to bioequivalence testing and biophysical characterization.
PureCD™ - companion diagnostics. Pure Biologics is focusing its activities on helping clients take advantage of the FDA-driven approach to support co-development of
companion diagnostics alongside the R&D of novel pharmaceutical and biotherapeutics.
Internal R&D
-Development of a diagnostic screening test for early detection of selected cancers using serum-derived microRNA as biomarkers
-Development of antibody-based diagnostics of urological cancers
-Development of diagnostic tests for veterinary medicine
What business partners are we seeking?
-Pharmaceutical and biotech companies with R&D programs on biologics and innovative drug development, interested either in developing or producing new recombinant
proteins as therapeutics or as companion diagnostics to their small molecule or bio-therapeutics;
-Research-intense SMEs and Academic labs developing or utilizing, recombinant proteins or antibodies
-Entities working on assay development (e.g. for diagnostic tests) seeking custom solutions involving proteins/antibodies, interaction studies, process optimization
-Collaborative industrial and academic partners to participate in both large national and international R&D projects (e.g. EU Horizon 2020 framework)
-Possibilities of collaborative business portfolio development with other SMEs, particularly within the EU, as well as globally.
QUINTA-ANALYTICA
Address
Pražská 18c/1486
102 00 Praha 10 - Hostivař
Czech Republic
www
www.quinta.cz
Organisation Type
Company
Contact Person
Name
David Dvorak
Position
Business Manager
E-Mail
[email protected]
Short Description
Quinta-Analytica is a contract research organization (CRO) whose primary task is to supply pharmaceutical companies with analytical service. It specializes in studies and
analyses required by national regulatory authorities before a pharmaceutical company can bring its new products to market. Quinta-Analytica deals with complete analyses of
drug substances, final dosage forms and metabolites according to Good Manufacturing Practice (GMP), Good Clinical Practice (GCP) and/or Good Laboratory Practice (GLP)
guidelines. We offer Analytical method development, validation and transfer Quality control and release testing (including import testing to EU) ICH stability studies Testing of
dry powder inhalers Analyses of biopharmaceutical products under GMP, GCP and GLP Small scale syntheses of impurities coming from the stability studies Analyses of
complaint batches Clinical trials, primarily the BE studies/Phase 1 on healthy volunteers Pharmacokinetic/toxicokinetic studies in man and/or animals Main advantage of
Quinta-Analytica is the concentration of the analytical services at one place. Clinical unit with 44 beds, most-modern bioanalytical laboratory, laboratory for
biopharmaceuticals, quality control labs, ICH stability chambers, analytical method development department and headquarters are located on one address. It enables to
provide complete service (“turnkey contract”) or customized services in accordance to the sponsor’s requirements.
SCIENION AG
BioPartnering
Address
Volmerstr. 7B
D-12489 Berlin
Germany
www
www.scienion.com
Organisation Type
Company
Contact Person
Name
Ron Wolbert
Position
Sales
E-Mail
[email protected]
Short Description
SCIENION AG is a leading supplier of quality instrumentation and services for low volume liquid handling. Proprietary technologies include piezo electric dispensing, surface
modifications and microarray manufacturing for diagnostics, pharmaceutics, veterinary, plant and food analytics and research. Based on SCIENION's core competencies in ultralow volume liquid dispensing, assay miniaturization, and microarray manufacturing, we provide our customers with an integrated product portfolio facilitating a number of
applications: multiplex assays, DNA microarray production, biosensor loading, miniaturized PCR, peptide microarrays, protein microarrays, cell deposition. SCIENION's product
portfolio comprises hardware, consumables and services. Systems and software are characterized by its versatility, precision and robustness. Founded in 2000 in Berlin as a
spin-off of the Max-Planck-Institute for Molecular Genetics, the privately held company today operates from two sites, Dortmund and Berlin. In December 2011 SCIENION
founded an US subsidiary in Princeton, New Jersey to start selling its products and services directly into the North American market. SCIENION AG is certified according to DIN
EN ISO 9001:2008 for the development, manufacture and sales of dispensing systems and microarrays.
Selvita S.A.
Address
ul. Bobrzyńskiego 14
30-348 Kraków
Poland
www
www.selvita.com
Organisation Type
Company
Contact Person
Name
Alicja Małysiak
Position
Business Development Manager
E-Mail
[email protected]
Short Description
Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at speedy and cost-effective introduction of efficacious
and safe drugs to the market. The areas of our activity include: Research on new chemical entities originating from Polish universities or resulting from Selvita's own discovery
programs Integrated fee-for-service drug discovery projects based on medicinal chemistry, biology and pharmacology services Target-based solutions - advanced protein
modeling solutions Drug discovery - custom in-silico library construction Lead generation - optimization of lead compounds Contract synthesis and syntheses paths optimization
Information technology for research projects.
Shanghai Biopharmaceutics Industry Association
BioPartnering
Address
Rm.305, #500, Bibo Rd
Zhangjiang Hi-tech Park
Shanghai 201203
www
www.sbia.org.cn
Organisation Type
Other
Contact Person
Name
Shaoxiong Chan
Position
Executive President
E-Mail
[email protected]
Short Description
Shanghai Biopharmaceutics Industry Association (SBIA) was established in Dec. 19th 2002. Currently, SBIA has 212 members located in East China, whose sales scale has
reached over 200 billion RMB. They are mainly active in the health related fields of chemicals, biologics, TCM, medical devices, business, Services etc, covering the whole
industrial chain of modern biotechnological and pharmaceutical field from R&D, production to distribution. SBIA has set up six working divisions: membership, consulting,
information, IP, legal departments and “C.C. Tan Life Science Award” administrative office. SBIA acts as a bridge between the government management departments and
enterprises, providing strategic studies, industry planning, industry reports, industry appeals to the government; offering policy, industry research, project application,
information consultant, talent recommendation, patent agent and legal aid to the members. SBIA also helps national enterprises go abroad through international technological
exchanges, communications and the introduction of advanced technology and products. Meanwhile, SBIA is the organizer of “C.C. Tan Life Science Award”, which was approved
by the Ministry of Science and Technology of the P.R.C.
SKAN AG
BioPartnering
Address
Binningerstr. 116
CH-4123 Allschwil (Basel)
Switzerland
www
www.skan.ch
Organisation Type
Company
Contact Person
Name
Alessandro De Cesaris
Position
Sales Manager, dipl. Ing. FH, exec. MBA
E-Mail
[email protected]
Short Description
SKAN - Together always one step ahead
The 1968 founded SKAN, belongs to the pioneer companies in the area of cleanroom equipment and design of Isolators for the pharmaceutical industry. Innovative products,
client specific solutions as well as an efficient service organization have made SKAN a market leader and important partner of industry and research laboratories worldwide.
The activity of SKAN is focused on the following areas: Cleanroom technology, Isolator technology, Contamination Controls, Maintenance and Service, as well as material
Qualification.
The core competence of SKAN AG lies in solving the application specific cleanroom technology issues into functional and validatable concepts, equipment and products. The
entire problem solving application involves process and equipment engineering over to design qualification up to and including equipment qualification (IQ/OQ and PQ) at the
clients site - including complete GMP qualified documentation.
A strong research and development department provides the scientific process basis for the governmental acceptance and the validate ability of processes and products.
Stowarzyszenie BIOREGION Wielkopolska
Address
Złotniki, ul. Krzemowa 1
62-002 Suchy Las
Poland
www
www.bioregionwielkopolska.pl
Organisation Type
other
Contact Person
Name
Urszula Mikiewicz
Position
Członek Zarządu
E-Mail
[email protected]
Short Description
BioRegion Wielkopolska is an organization orientated on integration and promotion of the biotechnological, medical (life science) industry in Greater Poland Area. BioRegion
Wielkopolska provides access to qualified employees and researchers with various expertise. BioRegion Wielkopolska offera an access to a broad database of research units,
companies and professionals active in the biobusiness. Bioregion’s database contains contact data of over 100 specialists in the field of biotechnology/medicine who have
documented record of professional experience. Moreover, the database consists of over as 300 students and graduates of life science Univeristiies, Research Institutes etc. We
make it easier for the businesses to establish cooperation through our vast foreign contact network in Central and Eastern Europe and Northern Europe (i.a. BioCity Turku,
Bavarian Biotech Cluster, European Federation of Biotechnology, Hungarian Biotechnology Association, Europa Bio) We also organize periodical meetings with leading bussines
and science specialists in the bio/med industry BioRegion Wielkopolska Association provides support toits members by joint marketing and promotional activities (shared
webpage, catalogue and video promoting the connection, advertisement in specialist press and on the Internet). Our aim is also to arrange joint attendance to the most
important local and international industry events.
AdvaChemLab Ltd.
BioPartnering
Address
Topazowa 8
61-680 Poznań
Poland
www
www.advachemlab.com
Organisation Type
Company
Contact Person
Name
Tomasz Grabarkiewicz
Position
CEO
E-Mail
[email protected]
Short Description
AdvaChemLab Ltd., founded in 2007, is an innovative chemical development company based in Poland, focusing on providing its e nd-user clients and partners in the
pharmaceutical and fine chemical industries with pioneering chemistry for asymmetric synthesis. Specifically the company is focused on chiral ligands, chiral catalysts and chiral
biulding blocks (i.e.amino acids). We are based in a modern organic chemistry laboratory with all the associated equipment and facilities expected for small to medium scale
synthetic chemistry. We have excellent onsite access to a full array of spectroscopy and characterisation techniques including NMR, MS, X-ray, UV, HPLC, GC/GC-MS.
Bioscientia s.c
BioPartnering
Address
Ogrodowa 2/8
61-820 Poznań
Poland
www
Organisation Type
Company
Contact Person
Name
Mirosława Skupińska
Position
CEO
E-Mail
[email protected]
Short Description
Bioscientia s.c is a dynamic biotechnological company with focus on providing unique and innovative for veterinary. The main area of development of the company is research
of efficient and sensitive diagnostic LDF-type tests and animal protection products. Bioscientia utilizes state-of-the art scientific and technological solutions and hence produces
the best quality diagnostic tests which can be used both by veterinarians and individuals. The unique portfolio of the products on offer is perfect answer to the demands of the
ever-changing animal pathogen diagnose market. Our priority is the quality of the products we provide and customer satisfaction.
Centre for Bio-Medical Education Ltd.
BioPartnering
Address
Kobaltowa 6
62-002 Złotniki
Poland
www
Organisation Type
Company
Contact Person
Name
Urszula Mikiewicz
Position
CEO
E-Mail
[email protected]
Short Description
Centre for Bio-Medical Education is a modern competence centre that focuses on technology transfer, development of research projects, as well as training in the biotech and
life sciences. Our offer is addressed both for single units as well as for groups. Centre for Bio-Medical Education has experienced staff and modern laboratory facilities enable to
deploy new technologies. Centre staff members are looking for projects that the careful analysis and research can be transformed into a unique intellectual property. Research
and development activities are focused mainly on supporting projects related to the development of new therapeutic strategies (including new active substances) in areas such
as: diseases of the central nervous system, cardiovascular, autoimmune and infectious diseases, and diagnosis and prevention of these diseases. The Centre is also interested in
solutions in the field of medical devices characterized by the large market potential.
DNA Research Center
BioPartnering
Address
Mickiewicz 31
60-835 Poznań
Poland
www
www.cbdna.pl
Organisation Type
Company
Contact Person
Name
Jacek Wojciechowicz
Position
CEO
E-Mail
[email protected]
Short Description
DNA Research Center is a biotechnological company. We develop and provide genetic diagnostic services in the field of medicine, microbiology and veterinary medicine using
ultramodern molecular research technologies. In result of our R&D work, which has been codnucted since 2006, several new solutions and diagnostic test are already
implemented and commercialized . This includes new molecular screening tests for identifying predisposition towards genetic diseases, cancers and microbial infections in
particular.
FutureSynthesis Ltd.
BioPartnering
Address
Rubież 46
61-612 Poznań
Poland
www
www.futuresynthesis.pl
Organisation Type
Company
Contact Person
Name
Joanna Chmielewska
Position
CEO
E-Mail
[email protected]
Short Description
FutureSynthesis Ltd. is an innovative nanotechnological company specialized in chemical synthesis and characterization of the natural compounds, particularly nucleic acids.
Our leading products are RNA and DNA nucleic acids synthesized for clients’ individual requests. Apart from those, our company offers 2´-O-MeRNA modified oligonucleotides
as well as fluorescence labeled nucleic acids and unique modifications, a long with combinations of modifications, useful in complex biotechnological experiments. We are
following the latest trends in the nucleic acid field and we subsequently include them in our offer. Highly specialized staff and the latest diagnostic equipment guarantee the
professional approach to each request and the top quality of our service. We are expanding our offer basing on intensive co-operation with science community. The result of
this partnership is the possibility of synthesis of biomolecules, such as: peptides, triphosphates or phosphoramidites. Follo wing the highest standard and purity of our products,
we perform qualitative analysis at every step of production using high-tech detection methods. Our routine analyses include analytical method using high-performance liquid
chromatography (HPLC), UV-VIS analysis, elementary and mass analysis (MALDI-TOF) as well as nuclear magnetic resonance analysis (NMR). We constantly aim to improve the
quality of our service, therefore, we are able to carry out additional analyses to fully characterize and specify our product.
Medibase Ltd.
BioPartnering
Address
62-002 Suchy Las
Poland
www
www.medibase.pl/
Organisation Type
Company
Contact Person
Name
Piotr Kwiatek
Position
CEO
E-Mail
[email protected]
Short Description
Medibase promotes safe drug therapy by providing specialized databases of drugs for healthcare professionals. Our databases facilitate the work of physicians and help to save
costs of medical institutions by reducing the time needed to consult and delivering accurate selection of drugs. Medibase sug gest recommendations for the amendment of the
dose and the possibility of using alternative medicines and provides information on additional patients monitoring. Our databases are consistent with Polish drugs registry and
contain the active ingredient, Polish trade names and generic names. Due to its design, all Medibase products can be quickly integrated within Electronic Medical Records
systems, portals, mobile solutions. CAS numbers, and ATC codes, NPLID and EAN, can link Medibase. Medibase solution is the reference in the Nordic countries and Benelux,
and is increasingly being used by Italian, Austrian and Spanish doctors and pharmacists. Medibase system consists of 4 specialized database: SFINX / PHARAO, GRAV / LACTBASE
and RENBASE SFINX This database contains concise information on interactions and verified information on the impacts and recommendations for more than 17,000 pairs of
interactions with drugs, herbal products and food. Information presented is classified according to the clinical significance and the level of proof. PHARAO Is a database of over
1400 drugs and contains 9 selected adverse reactions: anticholinergic effect, risk of bleeding, constipation, orthostatism, QT-prolongation, renal toxicity, sedation, risk of
seizures, serotonergic effect. Contains information on adverse reactions recorded on 4-point scale. Includes implications and recommendations associated with adverse events.
Pharao database is an extension to Sfinx database and presents risk profile on the basis of the pharmacodynamics properties of drugs. Pharao contains over 12,000 assessed
patient risk profiles. GRAV/LACTBASE Is a database of over 1,000 drugs with indications for women during pregnancy and lactation. Contain recommendations regarding the
selection of drugs, dose modifications and treatment monitoring methodology. Gravbase and Lactbase support decision-making by providing concise information on the safety
of various drugs during pregnancy and lactation. There are also information on vitamins and frequently used substances like caffeine or nicotine. Gravebase and Lactbase use
modern search methods that allow rapid assistance in decision-making when prescribing or dispensing of medicines for women. RENBASE Database of 1000+ drugs in the
treatment of kidney diseases. Includes recommendations and the proposed dose of drugs for the treatment of renal failure and dialysis. Additional features are available
Renbase, for example automatic calculation of GFR based on creatinine clearance, or on the basis of descriptive data of the p atient (age, sex, weight, height). The reduction
efficiency kidney (or kidney failure) is an important, but still often overlooked factor for drug dosing. Renbase contains information on recommendations regarding dose
modification and the use of any drug during renal failure and different methods of dialysis. In Recommendations for clinical and laboratory monitoring at prescribing /
dispensing of a specific agent are also provided.
PozLab Ltd.
BioPartnering
Address
Parkowa 2, 60-775 Poznań
Poland
www
www.pozlab.pl
Organisation Type
Company
Contact Person
Name
Anna Krause
Position
CEO
E-Mail
[email protected]
Short Description
PozLab Ltd. is a research and development services laboratory executing orders for formulation development, pharmaceutical analysis and microbiological testing for domestic
and international customers. The company has been on the market since 2010. We have experts with interdisciplinary knowledge and great experience in the area of research
and development of innovative medicines, generics, dietary supplements and cosmetics products, working together as a team for many years (previously - in the Polish R&D
department of an international pharmaceutical company) Extensive experience and broad knowledge as well as modern infrastructure in the GMP standard makes it possible
to execute customers' orders in the field of: - development of formulations of medicilan products, dietary supplements and cosmetics, - quality control in analytical,
microbiological as well as physical and chemical tests, - development and validation of analytical, microbiological as well as physical and chemical methods, - stability tests, compiling registration documentation, - preservation testing - monitoring the production environment
Poznań University of Life Sciences; Faculty of Animal Breeding and Biology
BioPartnering
Address
Wojska Polskiego 28
60-637 Poznań
Poland
www
www.up.poznan.pl/whibz
Organisation Type
academia
Contact Person
Name
Małgorzata Szumacher-Strabel
Position
Dean
E-Mail
[email protected]
Short Description
The Faculty of Animal Sciences (present name Faculty of Animal Breedings and Biology) was created on November 17, 1951 as a part of Agricultural College of Poznań. This was
made possible due to the decree of the Council of Ministers, that enabled a creation of new departments and allowed to shift others from the Department of Agriculture and
Forestry of the University of Poznań. In 1998 the Faculty changed its name to the Faculty of Animal Breedings and Biology, in order to emphasise the expand of its research
activity onto the fields related to animal biology and genetics. The Department was granted the right to award doctoral degre es in 1958 and to award habilitation degree in
1961. In 2013 the Faculty was conferred the right to promote scientists to the title of doctor of biological sciences. The latest parametric evaluation of the scientific units
carried out by the Ministry of Science and Higher Education rewarded the Faculty with high A category. Mission The most important aims of the Faculty are: • educating highly
skilled specialists for food industry • popularizing knowledge, supporting technological and biological advancement in agriculture with a special focus placed on the
Wielkopolska region. These aims are achieved by ongoing improvement of teaching curricula and active contribution to scientific research, financed by the University,
government agencies and international programmes. Academic and Research Staff There are 150 employees of the Faculty, including 43 professors and habilitated doctors, 57
doctors, 5 assistants and lecturers with masters degree, as well as 45 technical assistants and administration employees. Scientiﬁc activity The research activity is focused on: •
modern techniques and technologies of animal breeding and raising • improvement of production and functional genetic features of animals • population genetics • functional
genomics and epigenomics • molecular and cellular endocrinology and neuroendocrinology • impact of exogenous and endogenous factors on animal organisms metabolism •
animal anatomy and histology • technology of feed production and preservation • animal alimentary canal microbiology • qualitative analysis of animal origin products •
biology, breeding and reintroduction of endangered and extinction approaching animal species • ecology, aetiology, evolution and conservation b iology • biology and
biotechnology of animal reproduction • socio-economic determinants of agri and rural tourism development. Study opportunities Animal Sciences Biology Tourism And
Tourism Management Nature Tourism Veterinary Medicine European Master Of Comparative Morphology Institute of Veterinary Medicine Institute of Zoology: Division of
Animal Anatomy Division of Animal Histology and Embryology Division of Apidology Division of Inland Fisheries and Aquaculture Division of Zoology Laboratory of Neurobiology
Department of Animal Physiology and Biochemistry Department of Genetics and Animal Breeding Department of Genetics and Animal Breeding Division of Horse Breeding
Department of Cattle Breeding and Milk Production Department of Pig Breeding and Production Department of Small Mammals Breeding and Animal Origin Materials
Department of Rural Tourism Division of Poultry Science Department of Animal Nutrition and Feed Management Faculty Computer Room
Poznan University of Life Sciences, Faculty of Food Science and Nutrition, Department of
Biotechnology and Food Microbiology
BioPartnering
Address
Wojska Polskiego 48
60-627 Poznań
Poland
www
http://www.up.poznan.pl/kbimz
Organisation Type
academia
Contact Person
Name
Tomasz Jankowski
Position
Profesor
E-Mail
[email protected]
Short Description
The Department of Biotechnology and Food Microbiology is focused on research and educational programs which relate to food sciences. Current research includes, but is not
limited to, studies on: • Applied Microbiology (antimicrobial activity of microorganisms and their metabolites; microbial denitrification of drinking water; microbial adhesion to
solid surfaces; new raw materials and microorganisms for ethanol, lactic acid, propionic acid and diols fermentation), • Enzy matic Processes (low-temperature hydrolysis of
native starches with simultaneous ethanol fermentation; hydrolysis of chemically modified starches; transestrification of edible oils for biofuels; hydrolysis of proteins), •
Bioprocess Engineering (microencapsulation of food and pharmacological components; membrane separations; separation of molecules with use of aqueous two-phase
systems), • Food Biotechnology (probiotic bacteria and their influence on human health; prebiotics; functional foods; bacteriocins), • Environmental Biotechnology (removal of
organic pollutants with use of microorganisms and hydrophonic plants; cleaning of plastic packing for recycling with the use of microorganisms), • Mammalian and Insect Cells
(insect cells/baculoviruses expression system; virus infection and regulatory factors; production of recombinant proteins; proteins of influenza and papilloma viruses; human
colon in vitro; stable cell lines), • Genetics of Microorganisms (identification and diversity analysis of microorganisms; overexpression of heterologous proteins in G(-) and G(+)
bacteria, yeast, insect and mammalian cells; lactic acid bacteria phages; phage infection and phage-resistance; interaction of probiotic microorganisms with eucariotic cells).
Offers for Practice • consulting and development of new technologies at pilot plant scale (5, 30, 150 and 1500 liters fermentors equipped with monitoring and control systems),
• rental of pilot plant equipment for small and medium enterprises for research purposes, • development of bioprocesses in “clean-room” laboratory (safe work with GMO and
organisms of 2nd class biological hazard), • consulting on fermentation and biosynthesis processes, and sanitary standards in food manufacturing plants, • analysis of food and
environmental samples with the use of chromatography (HPLC, GC), • microbial and genetics analysis of food and environmental samples, • analysis of functional properties of
foods, • mechanical and rheological characteristics of food and pharmaceutical products. In 2005 the Department of Biotechnology and Food Microbiology was included as a
central unit into the Centre of Excellence “Food Biotechnology” coordinated by Poznan University of Life Sciences. In 2007 the Department was provided with structural funds
from the European Union in the Sector Operational Programme entitled “Enhancing the Competitiveness of Enterprises” for scientific and pilot plant equipment.
VitaInSilica Ltd.
BioPartnering
Address
62-002 Suchy Las
Poland
www
www.vitainsilica.pl
Organisation Type
Company
Contact Person
Name
Tomasz Puton
Position
CEO
E-Mail
[email protected]
Short Description
VitaInSilica Ltd. is a bioinformatics company represented by a group of professionals from bioinformatics, biotechnology, molecular biology and IT. We offer expertise and
experience in the application of bioinformatics tools to create a new quality in research. We are focusing on the application of Next Generation Sequencing (NGS) in developing
novel diagnostics for human diseases. Our expertise allows to reduce time of molecular and biological analyses, and to design laboratory experiments more precisely, what
reduces costs. Also, our software dedicated to biological data management allows organising and sharing the results of experiments in an efficient and user-friendly way. We
are working both with academia and business. We are here to help.
TAP Biosystems
Address
York Way Royston
SG8 5WY
United Kingdom
www
www.tapbiosystems.com
Organisation Type
Company
Contact Person
Name
Isabel Lambourne
Position
Sales Marketing Coordinator
E-Mail
[email protected]
Short Description
TAP Biosystems provides advanced automation systems and services to improve productivity in life sciences research, development & production. TAP will be showcasing: ambr
TM the advanced microscale bioreactor system for cell line selection and process optimisation applications Fill-It TM for automated screw-cap cryovial filling system for cell
bankingprodcing biomimetic 3D tissue models in standard plate formats RAFT TM for producing biomimetic 3D tissue models in standard plate formats.
BioPartnering
Address
Graiciuno 8
LT-02241 Vilnius
Lithuania
www
thermofisher.com
Organisation Type
Company
Contact Person
Name
Ingrida Micke
Position
Market Development Manager, Licensing & Commercial Supply
E-Mail
[email protected]
Short Description
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our
customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient
diagnostics and increase laboratory productivity. Our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – offer an unmatched
combination of innovative technologies, purchasing convenience and comprehensive support.
Thomson Reuters
Exhibitors #47a, BioPartnering
Address
1500 Spring Garden St.
PA 19130 Philadelphia
United States of America
www
http://thomsonreuters.com/pharma-life-sciences/
Organisation Type
Company
Contact Person
Name
Thomas Fogerty
Position
Marketing Specialist
E-Mail
[email protected]
Short Description
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. They combine industry expertise with innovative technology to
deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare, science and media markets, powered by the world’s most trusted
news organization. Thomson Reuters Life Sciences supports R&D productivity across the Pharma lifecycle with respected and comprehensive intelligence solutions. Offering
unbiased scientific, competitive, regulatory, and generics information, analytics, and expertise for your organization, Thomson Reuters Life Sciences empowers and enables
effective, evidence-based decision-making at every stage from discovery to launch and beyond.
Tosoh Bioscience GmbH
BioPartnering
Address
Zettachring 6
D-70567 Stuttgart
Germany
www
www.tosohbioscience.de
Organisation Type
Company
Contact Person
Name
Hans Vuijst
Position
Business Development Manager Europe
E-Mail
[email protected]
Short Description
Tosoh Corporation is a diversified global chemical company with a strong reputation in basic chemicals, petrochemicals, and specialty products. Since its founding in 1935,
Tosoh has expanded into high-value-added businesses, such as organic chemicals, bioscience, quartzware, and advanced electronic materials. Tosoh Bioscience’s product
portfolio encompasses GPC instruments and a comprehensive line of Toyopearl and TSKgel chromatography media and prepacked TSKgel HPLC columns. Tosoh Bioscience
offers chromatography solutions for research, drug discovery, medicinal chemistry, environmental analysis, manufacturing and other industrial applications for all common
modes of liquid chromatography, including IEC, HIC, RPC, HILIC, SEC and affinity.
UAB Spronk - Bio-NMR
Exhibitors #52a, BioPartnering
Address
A. Vienuolio g. 4
LT-01104 Vilnius
Lithuania
www
www.spronk3d.com
Organisation Type
Company
Contact Person
Name
Chris Spronk
Position
Director
E-Mail
[email protected]
Short Description
The Bio-NMR project (www.bio-nmr.net) is FP7 EU funded project that aims to further structural biology research in Europe, with a specific aim to involve Life Science research
institutes and industry by providing its knowledge and facilities. Spronk (www.spronk3d.com) is the representing partner of the Bio-NMR project at BioForum, and is
responsible for promoting structural biology in the new EU member states. The company specialises in NMR research for fundamental structural biology, and the production of
3D animations for life sciences which are at the core of the Bio-NMR information campaign for new EU member states.
University of Lodz
Address
ul. Nartutowicza 65
90-131 Łódź
Poland
www
www.uni.uni.lodz.pl
Organisation Typ
Academia
Contact Person
Name
Maria Głowacka
Position
University of Lodz contact person for BioForum 2014.
Marketing manager at the Accelerator University of Lodz Foundation, and StartMoney seed capital investment fund.
E-Mail
[email protected]
Short Description:
UNIVERSITY OF LODZ is one of the leading institutions of higher education in Poland. 12 faculties of the University provide programs in 60 fields and 170 specializations.
During BioForum 2014, University of Lodz presents an offer of research projects from Faculty of Biology and Environment Protection and from Faculty of Chemistry, and their
offer of services and cooperation possibilities for business and industry.
DEPARTMENT OF ORGANIC CHEMISTRY, FACULTY OF CHEMISTRY.
Project: Promising Cytotoxic and Phytotoxic Properties of Furan and Thiophene Aminophosphonates and Imines.
Project Manager: Prof. Jarosław Lewkowski1 [email protected]
Contractors:
Agnieszka Kuropatwa1 M.Sc. [email protected] – synthesis
Renata Kontek2 Ph.D. [email protected] – cytotoxicity
1Department
2Laboratory
of Organic Chemistry, Faculty of Chemistry, UL
of Cytogenetics, Department of General Genetics, Molecular Biology and Biotechnology, Faculty of Biology and Environmental Protection, UL
External partners:
Anna Agnieszka Klimczak M.Sc. and Prof. Janusz Szemraj – cytotoxicity, Medical University of Lodz
Piotr Rychter Ph.D. and Robert Biczak Ph.D. – phytotoxicity, Jan Długosz University in Czestochowa
The project concerns the studies on the synthesis and biological properties of a series of furan and thiophene derivatives bearing aminophosphonic or azomethine moiety.
These biological properties constitute the most important part of the project and consists of investigating in vitro cytotoxicity of synthesized compounds towards various cancer
cell lines. Two compounds were found to have quite interesting cytotoxicties, one of them, against human squamous esophagus cancer cell lines and the mechanism of this
cytotoxicity was established to be based on apoptosis. Studies on control human “healthy” cell lines demonstrated the lack of cytotoxicity towards “healthy” cells. The second
compound was effective against human colon cancer. Whilst the realization of the project, SAR studies are performed in order to design the compounds demonstrating higher
cytotoxicity with neutral action to control cells.
The second part of the project concerns studies on phytotoxic properties of aminophosphonic or azomethine derivatives of furan and thiophene in order to design compounds,
which may be applied in future as herbicides or plan protection agents. The future study includes the a pplication of biodegradable polymers for slow liberation of agents of
interest.
The project is realized in cooperation between the Department of Organic Chemistry, Faculty of Chemistry, the University of Łódź and several partners from Poland. The project
is managed in the Department of Organic Chemistry and compounds are synthesized in the Department. The Faculty and Department is equipped enough to conduct typical
synthetic studies (synthetic labs, NMR and IR spectroscopy, mass spectrometry). Cytotoxicity is investigated in the Department of Cytogenetics, Faculty of Biology and
Environmental Protection, University of Łódź and in the Department of Medicinal Biochemistry, Medical University of Łódź, while phytotoxic properties of studied compounds
are investigated in the Institute of Chemistry, Environmental Protection and Biotechnology, Jan Długosz University in Częstochowa.
DEPARTMENT OF GENERAL BIOPHYSICS, FACULTY OF BIOLOGY AND ENVIRONMENTAL PROTECTION UL
Project: “In vitro studies of phosphorus dendrimers as photosensitizer carriers in PDT therapy combined with hyperthermia” (VENTURES programme, Foundation for Polish
Science, co-financed by the EU European Regional Development Fund).
The Department of General Biophysics studies dendrimers - hyperbranched polymers. Due to dendritic structure they are promising materials for biomedical applications such
as antiamyloid agents or delivery systems for drugs, nucleic acids, etc. The main aim of the project is to design suitable delivery system based on phosphorus dendrimers for
photodynamic therapy of basal cell carcinoma in vitro.
Contact: Monika Dąbrzalska M.Sc. [email protected], phone: +48 42 635 41 47
DEPARTMENT OF PLANT PHYSIOLOGY AND BIOCHEMISTRY, FACULTY OF BIOLOGY AND ENVIRONMENTAL PROTECTION UL
The use of plants and in vitro cultures to obtain new pro-health and medicinal compounds, nutraceuticals, food and cosmetics dyes, antioxodants, ecological protective
products and bioacivators of plant resistance, insecticides. Micropropagation of usable, medicinal and endangered plants. Research on induction of natural plant defense
responses to infection and environmental stresses, like salinity, acid rain or trace metals. Development of innovative methods of storage of fruits and vegetables.
Contact: Katarzyna Bergier, Ph.D., [email protected], Marzena Wielanek Ph.D, [email protected], phone: +48 42 635 44 18
ACCELERATOR UNIVERSITY OF LODZ FOUNDATION
Accelerator University of Lodz Foundation supports the University of Lodz in commercialization of R&D results, and in cooperation of academia with companies.
Accelerator University of Lodz Foundation also manages a seed investment fund StartMoney, within which it invests in implementation of R&D results. The investments of
StartMoney fund realized in sectors of biotechnology, biology, chemistry and veterinary, which use R&D results from universities include:
CELLVET Sp. zo.o - the most modern laboratory in Poland offers the diagnostics and assistance in veterinary treatment. The company offers comprehensive services for a wide
range of clients involved in animal husbandry. The main element of the business is the introduction to the market in collaboration with veterinary clinics the innovative
regenerative medicine treatment based on the use of autologous stem cells and platelet-rich plasma (PRP). Cellvet also provides a wide range of microbiological tests and
genotyping including an analysis of the animals’ degree of kinship. Beside its commercial activity, Cellvet conducts a lot of R&D works in medicine and biotechnology.
Contact: Cellvet Sp. z o.o., Łódź, ul. Stanisława Dubois 114/116, 93- 465 Łódź, Piotr Wysocki Ph.D., phone: +48 608 379 947, [email protected]
BIOGENETICA INTERNATIONAL LABORATORIES Sp. z o.o. – an innovative company specializing in genetic diagnostic testing. State of the art laboratory has been founded in
Poznan, where R&D work is being carried out, and samples of genetic codes from patients from all over Europe are being analyzed. Tests are being sold to do ctors, outpatients
clinics, health centers, hospital, etc.
Tests are meant for dermatological conditions – acne, male and female balding, cellulite, psoriatic arthritis, and genital herpes, Cardio disease and FIT. As a result of few years
long cooperation of scientists from Poland and United States, the laboratory is also running research and development on further tests – for example pharmacological tests.
With the tests it is possible to check individual predispositions of a patient to many diseases, and determine individual sensitivity to medicines, which enables early
preventions, and allows choose the best possible treatment for potential, or already ill patients, as all predispositions to diseases as well as reaction to drugs are written down
in our DNA.
Biogenetica is always looking forward to contact potential new distributors from all over Europe.
Contact: Biogenetica Sp. z o.o., Joanna Jastrząbek - Chief Operating Officer, phone: +48 693 777 857, [email protected],
The participation of Lodz University in BioForum 2014 is part-financed from the Funds of National Center for Research and Development, within the “Creator if Innovation”
Programme.
Urząd Miasta Łodzi - Biuro Obsługi Inwestora
BioPartnering
Address
ul. Piotrkowska 104a
90-926 Łódź
Poland
www
www.uml.lodz.pl
Organisation Type
Institution
Contact Person
Name
Justyna Ciumaszko
Position
Coordinator Team Services Investor
E-Mail
[email protected]
USP Life Sciences
BioPartnering
Address
Poleczki 35
02-022 Warsaw
Poland
www
www.uml.lodz.pl
Organisation Type
Company
Contact Person
Name
Izabela Klockowska
Position
R&D Portfolio Manager
E-Mail
[email protected]
Short Description
USP Life Sciences is a separate company within USP Group, where belongs also USP Zdrowie, OTC market leader in Poland. USP Life Sciences invests private money in R&D
projects in area of biomedicine. The company` s strategy is to commercialize projects with protected Intellectual Property and business potential.
VWR International Sp. z o.o.
Address
Limbowa 5
80-175 Gdańsk
Poland
www.pl.vwr.com
Organisation Type
Company
Contact Person
Name
Position
Marketing Coordinator
E-Mail
Short description
At VWR, we enable science by supplying critical products to the world's top companies in the pharmaceutical, biotech, industrial, educational, governmental and healthcare
industries. VWR Life Science is committed to supporting Genomics, Proteomics, Cell biology, Microbiology and many other areas of life science research by providing enabling
research products that are innovative, timely and of consistently high quality. We provide our customers with an expansive choice of premiere products, such as chemicals,
equipment, instruments, apparel and consumables, from a vast group of leading scientific manufacturers like VWR Collection, Amresco, GE Healthcare, Pall Life Sciences,
Thermo Scientific, Corning, BD, Eppendorf, Applichem, Biotium, BTX, Quanta, Omega Bio-Tek, Polyplus, Origene, Biotix, Hoefer, 5Prime, Brand and many others.
Solutions to all your Life Science needs in one place....
VWR offers you complete solutions for all your work in:
•
Genomics
•
Proteomics
•
Cell Biology
Check out our website to see the newest tool - IgGy!
Find your antibodies using IgGy, the Antibody Selector! Quickly find the specific antibody you need from VWR's broad portfolio. VWR offers:
•
Hundreds of thousands antibodies
•
Expanding Supplier Base
•
Multiple Species
•
Multiple Conjugations
•
All Major Applications
VWR – we enable science!
Wrocławskie Centrum Badań EIT + Sp z o.o. (Wrocław Research Centre EIT + Ltd.)
Address
Stabłowicka 147
54-066 Wrocław
Poland
www
www.eitplus.pl
Organisation Type
Contact Person
Name
Katarzyna Krauzy-Dziedzic
Position
Team member of Life Science Department in Wroclaw Research Centre EIT+ Ltd
E-Mail
[email protected]
Short Description
Wrocław Research Centre EIT+ It is considered as first Research&Technology Organization (RTO) based in Poland currently realizing research and infrastructure projects. At
Pracze Campus, within Lower Silesian Materials and BioMaterials Centre the new R&D Center is being established comprising complex of interdisciplinary laboratories I total of
23 ha of dedicated area, equipped with high-class research equipment and apppriate certificates. It is unique place for cooperation of scientists, commercial partners as well as
clusters' associated organizations. One of our main research domains- project BioMed (''Biotechnologies and Advanced Medical Technologies''), concentrates on research of
novel methods of therapy, diagnostics and prophylaxis of civilization, infectious, and oncological diseases. Within the BioMed project we are realizing 23 researc tasks
protection and research commercialization. Our cooperation offer includes: Contact research, Commercialization and technology transfer, Joint and cofinanced research
projects, Support in obtaining research grants, Intellectual property management, Research projects management and Technical and business advice. Projects office:
Wrocławskie Centrum Badań EIT+ (Wroclaw Research Centre EIT+) ul. Stabowicka 147 54-066 Wrocław, Poland Phone: (+48) 71 720 16 01 [email protected] www.eitplus.pl
Wrocław Technology Park
Address
Muchoborska 18
54-424 Wrocław
Poland
www
www.technologpark.pl
Organisation Type
Other
Contact Person
Name
Ewelina Stelmach
Position
Laboratory specialist
E-Mail
[email protected]
Short Description
The objective of Wrocław Technology Park (WTP) is to create conditions for the use of scientific and indrustial potential and to simulate the advanced technologies industry.
The total office, laboratory and production space of the Park is over 40,000 square meters. Nowadays WTP hosts 10 laboratorie s, e.g Laboratory and Prototype Workshop for
Chemistry and Biotechnology, Laboratory and Prototype Workshop for Material and Biomedical Engineering, equipped for example with: large-scale mixers, high-pressure
homogeniztor, gas and liquid chromatographs. WPT has also a workshop designed and fullyequipped for organic synthesis purpose. Beside basic activities, like renting office
and laboratory space and sharing technological equipment for tenants, WTP realizes R&D projects in cooperation with companies from Technology Park and also transfers to
them financial aid (de minimis). WTP performs ordered analysi and organizes specialist trainings from biotechnology and pharmacy well. Wrocław Technology Park is also a
coordinator of the NUTRIBIOMED cluster – a scientific and industrial consortium. The financial and infrastructural support of the coordinator provides the opportunity for
designa and assembling of modern technological line for the production of dietary supplements, nutraceuticals and biomedical preparation. The top quality equipment and the
technological design simplify the development of new technologies and products. The line is almost fully-automated. Major utillity is focused of the technologies, which have
been tested primarily on the laboaratory scale. The technical operations are performed by the qualified personnel according to Hazard Analysis and Critical Control Point
(HACCP) system. Clean-In-Place (CIP) unit combined with continuous microbial testing and implementation of GMP and GHP systems guarantees the highest quality production
and safety. Wrocław Technology Park has also an experience in participating in the large-scale R&D projects. WPT took part in the European XFEL (X-ray Free-Electron Laser)
projects and cooperated within it for example with the European Organization for Nuclear Research CERN from Geneva and science institution DESY from Hamburg. Projects
aims to create a large scale laser on free electrons, and WTP part concerned on the creation and production of cryogenic line for cooling laser.
WTS Rzecznicy Patentowi - Witek, Śnieżko i Partnerzy
Address
Rudolfa Weigla 12
53-114 Wrocław
Poland
www
www.wtspatent.pl
Organisation Type
Company
Contact Person
Name
Rafał Witek
Position
Partner
E-Mail
[email protected]
Short Description
The WTS Patent Attorneys - Witek, Śnieżko & Partners is a patent attorneys practice whose goal is to provide aid in all matters connected with the protection of intellectual
property rights, their transfer and commercialisation. The partnership was formed in 2002 as an initiative of founder partners, who made the choice to merge their experience
gathered over several years at other patent agencies. The patent attorneys representing the practice are licensed to conduct all manner of cases dealing with IP protection,
both before Polish administrative bodies and their counterparts in the European Union, meaning the European Patent Office (EPO) as well as the Office of Harmonisation of the
Internal Market (OHIM). The firm has offices in Wrocław and Warsaw, with the Munich office having been opened in 2004. Due to the professional qualifications of the
partners, right from its inception, the partnership has specialised in the protection of IP in the areas of biotechnology, chemistry, pharmacology, and medicine as well as in
trademark cases. Our services include: the preparation and conduct of patent application, utility, and industrial model proceedings; registration of trademarks in Poland and
abroad; registration of novel plant varieties; representation of parties before appropriate courts in all contested matters and in connection with the infringement of exclusive
rights; patent or trademark invalidation proceeding; and the evaluation of the possibilities of successfully conducting the above proceedings. In matters concerning the
commercialisation of IP, our firm aids companies in finding partners, securing the rights of parties participating in trade negotiations as well as in the drafting of contracts and
agreements. The staff of WTS Patent Attorneys has always developed along with the firm´s growth. In organising and attending various schooling sessions, we continually
augment our skills and abilities. This approach is the direct result of our conscious choice to specialise in life-science and pharmaceutical innovation, and we currently comprise
the largest team of specialists in these areas on the Polish market. We strive to meet the expectations of the ever growing number of innovative companies in Poland, and to
actively participate in their development. We would also like our potential clients know that we initiate any relationship with a pote ntial client by attempting to understand
their needs and requirements. For this reason, our services are individual in nature and are always tailored to the particular requirements of each client. We invite you and your
Company to make use of our services, in the firm belief that your success is our success as well.
YBUX s.r.o.
Address
Haasova 27
Brno 616 00
Czech Republic
www
www.ybux.eu
Organisation Type
Other
Contact Person
Name
Romana Zaoralova
Position
Specialist for Molecular Biology and Cytoganatics
E-Mail
[email protected]
Short Description
ABOUT THE ORGANISATION, HISTORY: YBUX is a company with a 18-years history that is involved in the tissue based diagnostics, molecular genetics, cytology and the field of
in-vitro-fertilization. With less than 20 employees, headquarters in Brno and offices in Prague and Bratislava, YBUX is highly flexible and able to provide a targeted and
personalised service to the customers. EXPERIENCE, SPECIAL KNOW HOW: YBUX completely equipped most IVF centres in the region of Czech and Slovak Republics. Seventeen
years of cooperation as an exclusive distributor of Dako pathology portfolio in Czech Republic. Since 2014 we produce Yi TPMT diagnostic kit for SNP detection based on a realtime-PCR. PRODUCTS ON THE MARKET: Pharmacodiagnostic kit based on a real-time-PCR SNP detection called Yi TPMT. To participate in a MPO CR (Ministry of Industry and
Trade of the Czech Republic) grant project with the University of Veterinary and Pharmaceutical Sciences, YBUX uses its own PCR laboratory equipped with a state-of-the-art
technology. Besides that, YBUX is local distributor of more than 20 international companies, such as Dako (www.dako.com), Oxford Gene Technology (www.ogt.co.uk) or MTG
(www.mtg-de.com). Our company’s services are not limited to the Czech and Slovak Republic as we target another Central European markets as well.
Zakłady Farmaceutyczne Polpharma S.A.
Address
Pelplińska 19
83-200 Starogard Gdański
Poland
www
www.polpharma.pl
Organisation Type
Company
Contact Person
Name
Piotr Zień
Position
Assistant
E-Mail
[email protected]
Short Description
Following the increasingly better solutions for patients, the Company created a special business unit Polpharma Biologics and built a state-of-the-art research and development
center in Gdansk Science and Technology Park. The laboratory is the largest of its kind in Poland. It is equipped with the most modern equipment enabling efficient work with
complex monoclonal antibodies and other therapeutic proteins. World-class instrumentation, advanced technology and highly skilled staff will ensure the highest quality of
prepared products on the a global level. At the end of 2012, Polpharma finished completed the first phase of the investment. Research laboratories with surface area of 600
m2 surface enable the development and optimization of protein production. Analytical laboratories were also launched, enabling for example the quality assessment of the
final form of the drug and modern analytical techniques development.

Exhibitors #24, Biopartnering

Transcription

Similar documents

World Youth Day

SIMPLE SOFTWARE

Prezentacja InvestinPoland

Molluscs from Early Frasnian Goniatite Level at Kostomłoty in the

HA 2014 invitation lekki.cdr

Historical Background Briefing Conditions of

Prezentacja nowego produktu

Newsletter VALIANS 07 2016

Dr. Mikołaj Piniewski

Katowice, Poland / 12-13.03.2016 Lublin, Poland / 28